# MDT Discussion Log — 2026-01-22_18-41-31
Generated automatically by MDT Pipeline.



## CASE (structured JSON)

```
{"CASE_CORE":{"ADJUVANT_TREATMENT":{"cycles_or_courses":"6","given":"Yes","regimens":["TP"]},"BIOMARKERS":{"AFP":"Unknown","CA125":"Unknown","HER2":"Unknown","MSI":"Unknown","PDL1_CPS":"Unknown","TMB":"Unknown"},"BRCA1":"Unknown","BRCA2":"Unknown","CURRENT_STATUS":"On maintenance niraparib; ECOG 1; recent imaging without pelvic recurrence.","DIAGNOSIS":{"components":["Adenocarcinoma","High-grade serous carcinoma"],"histology":"High-grade serous carcinoma","laterality":"Bilateral","primary":"Ovarian cancer","site":"Ovary"},"ECOG":"1","GENOMICS":{"HRD_STATUS":{"method":"Unknown","result":"Positive","score":"Unknown"},"alterations":[],"testing_date":"Unknown","testing_performed":"Yes","testing_platform":"Unknown"},"HRD":"Positive","INITIAL_TREATMENT":"Yes","LINE_OF_THERAPY":[{"concurrent_bevacizumab":"No","cycles_completed":"1","cycles_planned":"Unknown","discontinuation":{"detail":"Switched to TP chemotherapy","reason":"Other"},"end_date":"2021-09-07","in_clinical_trial":"No","intent":"First_line","line":"1L","pfs_days":"41","regimen":"顺铂50mg腹腔化疗","response_assessment":{"best_response":"Unknown","ca125_response":"Unknown","response_criteria":"Unknown","response_date":"Unknown"},"start_date":"2021-09-06"},{"concurrent_bevacizumab":"No","cycles_completed":"6","cycles_planned":"6","discontinuation":{"detail":"Completed 6 cycles","reason":"Completed"},"end_date":"2022-03-22","in_clinical_trial":"No","intent":"First_line","line":"1L","pfs_days":"Unknown","regimen":"TP","response_assessment":{"best_response":"Unknown","ca125_response":"Unknown","response_criteria":"Unknown","response_date":"Unknown"},"start_date":"2021-10-18"},{"concurrent_bevacizumab":"No","cycles_completed":"Unknown","cycles_planned":"Unknown","discontinuation":{"detail":"Temporarily stopped due to adverse reactions and low platelets; restarted 2022-05-23; held 3 weeks around hernia repair; currently continuing","reason":"Other"},"end_date":"Unknown","in_clinical_trial":"No","intent":"Maintenance","line":"1L","pfs_days":"Unknown","regimen":"尼拉帕利","response_assessment":{"best_response":"Unknown","ca125_response":"Unknown","response_criteria":"Unknown","response_date":"Unknown"},"start_date":"2022-04-Unknown"}],"MAINTENANCE":"Yes","MAINTENANCE_DETAIL":{"end_date":"Unknown","given":"Yes","regimens":["尼拉帕利"],"start_date":"2022-04-Unknown"},"NEOADJUVANT":"Unknown","PFI_days":"Unknown","PLATINUM_HISTORY":[{"PFI_days":"Unknown","end_date":"2022-03-22","evidence":"TP chemotherapy 6 cycles after primary surgery; no explicit relapse documented.","evidence_type":"Unknown","first_relapse_date":"Unknown","line":"1L","start_date":"2021-10-18","status":"Unknown"}],"PLATINUM_PFI_CURRENT":"Unknown","PLATINUM_STATUS":"Unknown","PLATINUM_STATUS_CURRENT":"Unknown","RELAPSE":"No","RELAPSE_DATE":{"date":"Unknown","evidence":"No relapse; pelvic MRI 2022-10-25 showed no abnormal soft tissue in pelvis.","type":"Unknown"},"SCENE":"Maintenance_surveillance_followup","STAGE":{"stage_basis":"Unknown","stage_system":"Unknown","stage_text":"Unknown"},"SURGERY_DONE":{"date":"2021-08-26","performed":"Yes","procedure":"Radical hysterectomy with bilateral salpingo-oophorectomy, pelvic mass resection, partial rectosigmoid resection, sigmoid colostomy, omentectomy, pelvic lymphadenectomy, appendectomy, paraaortic lymphadenectomy"},"TIMELINE":{"constraints":{"max_events":30,"min_events":3,"must_include":["first diagnostic imaging or pathology confirmation (if available)"],"ordering_rules":{"prioritize_last_event":true}},"events":[{"date":"2021-08-26","description":"Primary cytoreductive surgery including radical hysterectomy, bilateral salpingo-oophorectomy, bowel resection, omentectomy, lymphadenectomy, colostomy, appendectomy","event_type":"Surgery","key_result":"Multiple peritoneal sites and 6/24 lymph nodes positive for carcinoma","regimen_or_test":"Surgery"},{"date":"2021-08-26","description":"Pathology confirmed high-grade serous carcinoma of bilateral ovaries with widespread peritoneal involvement and nodal metastases","event_type":"Diagnosis","key_result":"High-grade serous carcinoma, bilateral ovaries; 6/24 lymph nodes positive","regimen_or_test":"Pathology"},{"date":"2021-09-06","description":"Intraperitoneal chemotherapy with cisplatin 50mg","event_type":"Chemo","key_result":"Completed over 2021-09-06 and 2021-09-07","regimen_or_test":"顺铂50mg腹腔化疗"},{"date":"2021-10-18","description":"Started TP chemotherapy, planned 6 cycles","event_type":"Chemo","key_result":"Completed 6 cycles, last on 2022-03-22","regimen_or_test":"TP"},{"date":"2022-03-22","description":"Last cycle of TP chemotherapy","event_type":"Chemo","key_result":"Adjuvant chemotherapy completed","regimen_or_test":"TP"},{"date":"2022-04-18","description":"Complete blood count showing thrombocytopenia","event_type":"Lab","key_result":"PLT:33","regimen_or_test":"Blood routine"},{"date":"2022-04-26","description":"Stopped niraparib due to strong adverse reactions","event_type":"Other","key_result":"Maintenance paused","regimen_or_test":"尼拉帕利"},{"date":"2022-05-23","description":"Restarted niraparib 1# qd","event_type":"Chemo","key_result":"Maintenance resumed","regimen_or_test":"尼拉帕利"},{"date":"2022-06-24","description":"Abdominal wall hernia repair at Zhongshan Hospital","event_type":"Surgery","key_result":"Niraparib held for 3 weeks around surgery","regimen_or_test":"Surgery"},{"date":"2022-09-27","description":"CT chest/abdomen showing small bilateral pleural effusions improved; pulmonary AV fistula and nodules similar to prior","event_type":"Imaging","key_result":"No new malignant findings reported; abdominal details deferred","regimen_or_test":"CT"},{"date":"2022-10-08","description":"CT showing liver segment VII hemangioma and left renal cyst, stable","event_type":"Imaging","key_result":"No new findings; chest to correlate with other exams","regimen_or_test":"CT"},{"date":"2022-10-25","description":"Pelvic MRI after ovarian cancer surgery","event_type":"Imaging","key_result":"No abnormal soft tissue in pelvis; follow-up recommended","regimen_or_test":"MR"},{"date":"2022-12-30","description":"Zhongshan Hospital evaluation: incisional hernia, low-density lesion in right liver lobe","event_type":"Imaging","key_result":"Blood count and liver/kidney function generally acceptable","regimen_or_test":"Imaging"},{"date":"2023-01-09","description":"Recent blood routine showed platelet count 34 (year not fully specified)","event_type":"Lab","key_result":"PLT:34 (interpreted from 'PLT:342022.5.23起恢复', year unclear)","regimen_or_test":"Blood routine"}]},"VISIT_DATE":"2023-01-09","first_relapse_date":"Unknown","last_platinum_end_date":"2022-03-22"},"CLINICAL_TRIALS":[],"LAB_TRENDS":{"labs":[{"analyte":"Other","history":[{"date":"2022-04-18","flag":"↓","value":"PLT:33"}],"latest":{"date":"2022-04-18","flag":"↓","value":"PLT:33"},"reference_range":"Unknown","unit":"Unknown"}],"milestones":[{"date":"2021-08-26","description":"Primary debulking surgery for ovarian cancer","type":"Surgery"},{"date":"2021-10-18","description":"Started TP chemotherapy","type":"ChemoStart"},{"date":"2022-03-22","description":"Completed TP chemotherapy","type":"ChemoEnd"},{"date":"2022-04-18","description":"Thrombocytopenia (PLT 33) on blood routine","type":"Other"}]},"MED_ONC":{"current_regimen":{"cycle_info":"Continuous oral maintenance; temporarily stopped 2022-04-26 and around 2022-06-24 surgery; currently continuing","last_admin_date":"Unknown","name":"尼拉帕利"},"genetic_testing":{"germline":[],"somatic":["HRD"]},"monitoring_points":[{"drug_or_class":"尼拉帕利","monitoring":["Monitor platelet count due to prior thrombocytopenia"]}],"planned_next_regimen":"Unknown","prior_systemic_therapies":["顺铂50mg腹腔化疗","TP"]},"NUC_MED":{"studies":[]},"PATHOLOGY":{"specimens":[{"components":["High-grade serous carcinoma","Myometrial leiomyomas","Chronic cervicitis"],"date":"2021-08-26","diagnosis":"Adenocarcinoma consistent with high-grade serous carcinoma","grade":"High-grade","ihc":[],"involvement_sites":["Left ovary","Right ovary","Left fallopian tube","Right fallopian tube","Uterine myometrium","Pelvic and abdominal peritoneum","Partial rectosigmoid colon from serosa to superficial muscle","Omentum","Left paracolic gutter peritoneum","Small bowel mesentery","Sigmoid mesentery","Appendiceal serosa","Pelvic lymph nodes","Para-aortic and mesenteric lymph nodes (some positive)"],"laterality":"Bilateral ovarian involvement","molecular":[{"result":"Positive","test":"HRD"}],"raw_text":"术后病理：标本类型:扩大子宫+双附件+巨大盆块+部分直乙结肠+盆腹腔多病灶肿瘤大小:左侧：3.5×2×1.5cm；右侧：6×5.5×4.5cm肿瘤侧别:双侧病理类型:腺癌，结合免疫组化结果（I2021-07819），符合高级别浆液性癌。其他部位情况:左输卵管:见癌累及右输卵管:见癌累及子宫内膜:萎缩改变宫颈:慢性炎子宫肌层:见癌累及；肌壁间平滑肌瘤（多枚，直径0.5-2cm）盆腹腔多部位病灶:（部分直乙结肠）见癌累及，自浆膜层浸润至浅肌层，肠管两切缘未见癌累及。（大网膜、大网膜及盆腔肿块、左侧结肠旁沟腹膜、小肠系膜肿瘤、乙状结肠系膜肿瘤）见癌累及.（阑尾及周围肿块） 浆膜层见癌累及。其他:送检淋巴结（6/24）见癌转移，其中：左盆腔淋巴结（1/4）；右盆腔淋巴结（3/8）；腹主肠系膜下方淋巴结（1/4）； 肠系膜下动脉上方淋巴结（1/2）；腹主动脉旁淋巴结（0/6）。","sample_type":"Surgical resection","site":"Uterus, bilateral adnexa, pelvic mass, rectosigmoid colon, peritoneum, omentum, appendix, lymph nodes","tumor_size":"Left ovary 3.5×2×1.5cm; right ovary 6×5.5×4.5cm","uncertainty_or_missing":["FIGO stage not provided","IHC panel details not provided"]}]},"RADIOLOGY":{"next_imaging_plan":{"modality":"Unknown","timing":"Unknown"},"studies":[{"anatomic_sites":["Lung","Pleura","Chest"],"date":"2022-09-27","findings":["Right upper lung arteriovenous fistula similar to prior","Right upper lung apical segment small nodule similar to prior","Left upper lung scattered tiny nodules","Small bilateral pleural effusions decreased compared with prior","Scattered chronic inflammatory and fibrotic changes in lungs","Atelectasis improved","Nodule at right cardiophrenic angle less apparent"],"impression":"Pulmonary AV fistula and nodules unchanged; pleural effusions and atelectasis improved","modality":"CT","trend_vs_prior":"Improved"},{"anatomic_sites":["Liver","Kidney","Spine"],"date":"2022-10-08","findings":["Hemangioma in liver right lobe segment VII similar to prior","Left renal cyst similar to prior","Localized uneven sclerotic change in lumbar vertebrae similar to prior"],"impression":"Stable hemangioma and renal cyst; spinal sclerosis unchanged; chest findings to correlate with other exams","modality":"CT","trend_vs_prior":"Stable"},{"anatomic_sites":["Pelvis"],"date":"2022-10-25","findings":["Postoperative changes after ovarian cancer surgery","No abnormal soft tissue mass in pelvis"],"impression":"No pelvic recurrence; follow-up recommended","modality":"MRI","trend_vs_prior":"Stable"}]},"TIMELINE":{"constraints":{"max_events":30,"min_events":3,"must_include":["first diagnostic imaging or pathology confirmation (if available)"],"ordering_rules":{"prioritize_last_event":true}},"events":[{"date":"2021-08-26","description":"Primary cytoreductive surgery including radical hysterectomy, bilateral salpingo-oophorectomy, bowel resection, omentectomy, lymphadenectomy, colostomy, appendectomy","event_type":"Surgery","key_result":"Multiple peritoneal sites and 6/24 lymph nodes positive for carcinoma","regimen_or_test":"Surgery"},{"date":"2021-08-26","description":"Pathology confirmed high-grade serous carcinoma of bilateral ovaries with widespread peritoneal involvement and nodal metastases","event_type":"Diagnosis","key_result":"High-grade serous carcinoma, bilateral ovaries; 6/24 lymph nodes positive","regimen_or_test":"Pathology"},{"date":"2021-09-06","description":"Intraperitoneal chemotherapy with cisplatin 50mg","event_type":"Chemo","key_result":"Completed over 2021-09-06 and 2021-09-07","regimen_or_test":"顺铂50mg腹腔化疗"},{"date":"2021-10-18","description":"Started TP chemotherapy, planned 6 cycles","event_type":"Chemo","key_result":"Completed 6 cycles, last on 2022-03-22","regimen_or_test":"TP"},{"date":"2022-03-22","description":"Last cycle of TP chemotherapy","event_type":"Chemo","key_result":"Adjuvant chemotherapy completed","regimen_or_test":"TP"},{"date":"2022-04-18","description":"Complete blood count showing thrombocytopenia","event_type":"Lab","key_result":"PLT:33","regimen_or_test":"Blood routine"},{"date":"2022-04-26","description":"Stopped niraparib due to strong adverse reactions","event_type":"Other","key_result":"Maintenance paused","regimen_or_test":"尼拉帕利"},{"date":"2022-05-23","description":"Restarted niraparib 1# qd","event_type":"Chemo","key_result":"Maintenance resumed","regimen_or_test":"尼拉帕利"},{"date":"2022-06-24","description":"Abdominal wall hernia repair at Zhongshan Hospital","event_type":"Surgery","key_result":"Niraparib held for 3 weeks around surgery","regimen_or_test":"Surgery"},{"date":"2022-09-27","description":"CT chest/abdomen showing small bilateral pleural effusions improved; pulmonary AV fistula and nodules similar to prior","event_type":"Imaging","key_result":"No new malignant findings reported; abdominal details deferred","regimen_or_test":"CT"},{"date":"2022-10-08","description":"CT showing liver segment VII hemangioma and left renal cyst, stable","event_type":"Imaging","key_result":"No new findings; chest to correlate with other exams","regimen_or_test":"CT"},{"date":"2022-10-25","description":"Pelvic MRI after ovarian cancer surgery","event_type":"Imaging","key_result":"No abnormal soft tissue in pelvis; follow-up recommended","regimen_or_test":"MR"},{"date":"2022-12-30","description":"Zhongshan Hospital evaluation: incisional hernia, low-density lesion in right liver lobe","event_type":"Imaging","key_result":"Blood count and liver/kidney function generally acceptable","regimen_or_test":"Imaging"},{"date":"2023-01-09","description":"Recent blood routine showed platelet count 34 (year not fully specified)","event_type":"Lab","key_result":"PLT:34 (interpreted from 'PLT:342022.5.23起恢复', year unclear)","regimen_or_test":"Blood routine"}]},"TOXICITIES":[{"attribution":"Probable","dose_modification":"Yes","onset_date":"2022-04-18","outcome":"Resolved","related_line":"1L","related_regimen":"尼拉帕利","severity":"Severe","toxicity":"Strong adverse reaction to niraparib with thrombocytopenia (PLT 33)"}]}
```


## FINAL MDT OUTPUT

```
Final Assessment:
HRD-positive, BRCA-wildtype high-grade serous ovarian carcinoma in first remission on maintenance niraparib. Current stable imaging [@2022-09-27|CT | CT][@2022-10-25|MR | MR] and low CA125 [@20230109|9701878 | LAB] support clinical remission. Key uncertainties include metastatic nature of stable lung nodules and lack of recent comprehensive restaging.

Core Treatment Strategy:
- Continue niraparib maintenance per HRD-positive status [@OH2201222 | Genomics] and guideline [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].
- Order updated CT chest/abdomen/pelvis now, as last staging was 3+ months ago [@2022-09-27|CT | CT].
- Consider FDG-PET/CT for metabolic assessment, especially of stable lung nodules.
- Obtain original surgical pathology for definitive IHC and FIGO stage.

Change Triggers:
- If platelet count drops below 100 [@unknown | LAB], dose-reduce or hold niraparib; reassess duration.
- If new metastasis on imaging, stop maintenance and start platinum-based chemotherapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15].

---
## References

### Guidelines

[@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17]
  Document: nccn_ovariancancer_v3_2025__v00000000, Page 17
  Content: i Germline and somatic BRCA1/2 status informs maintenance...

[@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]
  Document: nccn_ovariancancer_v3_2025__v00000000, Page 15
  Content: based chemotherapy,n
preferred for first
recurrence...

### Literature

### Clinical Trials

### Clinical Reports

[@2022-09-27|CT | CT]
  CT ID: 2022-09-27|CT | Date: 2022-09-27
  Content: 对比前片2021-09-01：右上肺动脉分支远端增粗且与右上肺静脉分支相通，右上肺静脉分支增粗，同前。右肺尖段见小结节同...

[@2022-10-25|MR | MR]
  MR ID: 2022-10-25|MR | Date: 2022-10-25
  Content: 对比2021-8-17：卵巢癌术后，阴道残端未见明显增厚，盆腔未见明显异常信号肿块，盆组及腹股沟淋巴结未见明显肿大，盆腔...

[@20230109|9701878 | LAB]
  LAB ID: 20230109|9701878 | Date: 2023-01-09
  Content: 糖链抗原125 6.45 U/ml (CA125) 人附睾蛋白4 78.30 pmol/L (HE4)...

[@OH2201222 | Genomics]
  Genomics ID: OH2201222 | Date: 2022-01-24
  Content: HRD 阳性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2...

[@unknown | LAB]
  LAB ID: unknown

```


## PIPELINE FLOW (Mermaid)

```mermaid
flowchart TD
  A[Load Case + Fingerprint] --> B[Load Reports]
  B --> C[Report Selection per Role]
  C --> D[Guideline+PubMed RAG]
  D --> E[Init Specialist Agents]
  E --> F[MDT Discussion Engine]
  F --> G[Trial Matching]
  G --> H[Final Chair Output]
  H --> I[Save Logs]
```


## TRACE EVENTS (Structured)

```json
[
  {
    "ts": "2026-01-22T18:38:03.308280",
    "event": "pipeline_start",
    "payload": {
      "visit_time": "2023-01-09 09:23:13.113000",
      "meta_info": "310103195705270044"
    }
  },
  {
    "ts": "2026-01-22T18:38:03.308841",
    "event": "case_fingerprint",
    "payload": {
      "case_fingerprint": "fa2f34f1e565"
    }
  },
  {
    "ts": "2026-01-22T18:38:03.839353",
    "event": "reports_loaded",
    "payload": {
      "lab_n": 152,
      "img_n": 24,
      "path_n": 0,
      "mut_n": 1,
      "cutoff_dt": "2023-01-10 09:23:13"
    }
  },
  {
    "ts": "2026-01-22T18:38:14.784756",
    "event": "reports_selected",
    "payload": {
      "lab": {
        "chair": [
          "20230109|5600622|2023-01-09",
          "20230109|8300382|2023-01-09",
          "20230109|9701878|2023-01-09"
        ],
        "oncologist": [
          "20230109|5600622|2023-01-09",
          "20230109|8300382|2023-01-09",
          "20230109|9701878|2023-01-09"
        ],
        "radiologist": [],
        "pathologist": [],
        "nuclear": []
      },
      "imaging": {
        "chair": [
          "2022-09-27|CT|2022-09-27",
          "2022-09-29|CT|2022-09-29",
          "2022-10-25|MR|2022-10-25"
        ],
        "oncologist": [],
        "radiologist": [
          "2022-09-27|CT|2022-09-27",
          "2022-09-29|CT|2022-09-29",
          "2022-10-25|MR|2022-10-25"
        ],
        "pathologist": [],
        "nuclear": [
          "2022-09-27|CT|2022-09-27",
          "2022-09-29|CT|2022-09-29",
          "2022-10-25|MR|2022-10-25"
        ]
      },
      "pathology": {
        "chair": [],
        "oncologist": [],
        "radiologist": [],
        "pathologist": [],
        "nuclear": []
      },
      "mutation": {
        "chair": [
          "OH2201222|2022-01-24"
        ],
        "oncologist": [
          "OH2201222|2022-01-24"
        ],
        "radiologist": [],
        "pathologist": [
          "OH2201222|2022-01-24"
        ],
        "nuclear": []
      }
    }
  },
  {
    "ts": "2026-01-22T18:38:14.788917",
    "event": "rag_key_facts",
    "payload": {
      "facts": "DIAGNOSIS: primary=Ovarian cancer; histology=High-grade serous carcinoma; components=Adenocarcinoma;High-grade serous carcinoma\nPATHOLOGY: Adenocarcinoma consistent with high-grade serous carcinoma\nPLATINUM: status=Unknown; pfi_days=Unknown\nBIOMARKERS: CA125=Unknown; AFP=Unknown; TMB=Unknown; MSI=Unknown; PDL1_CPS=Unknown\nMUTATION_REPORT: id=OH2201222; date=2022-01-24; full_text=HRD 阳性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PALB2 胚系和体系未检出致病突变（视为阴性）；RAD51D 胚系和体系未检出致病突变（视为阴性）；BRIP1 胚系和体系未检出致病突变（视为阴性）；BARD1 胚系和体系未检出致病突变（视为阴性）"
    }
  },
  {
    "ts": "2026-01-22T18:38:34.558567",
    "event": "rag_query",
    "payload": {
      "query": "HRD-positive, BRCA-negative high-grade serous ovarian carcinoma with widespread peritoneal metastases and nodal involvement post-platinum therapy, currently on PARPi maintenance with recurrent thrombocytopenia; histology: High-grade serous carcinoma"
    }
  },
  {
    "ts": "2026-01-22T18:38:34.558571",
    "event": "rag_hits",
    "payload": {
      "source": "guideline",
      "topk": 5,
      "n": 5
    }
  },
  {
    "ts": "2026-01-22T18:38:34.558572",
    "event": "rag_hits",
    "payload": {
      "source": "pubmed",
      "topk": 5,
      "n": 5
    }
  },
  {
    "ts": "2026-01-22T18:38:34.558574",
    "event": "rag_hits_merged",
    "payload": {
      "n": 10
    }
  },
  {
    "ts": "2026-01-22T18:38:53.377196",
    "event": "mdt_discussion_start",
    "payload": {
      "num_rounds": 2,
      "num_turns": 2
    }
  },
  {
    "ts": "2026-01-22T18:38:53.377352",
    "event": "mdt_initial_opinion_role_start",
    "payload": {
      "role": "chair",
      "order": 1
    }
  },
  {
    "ts": "2026-01-22T18:39:07.135337",
    "event": "mdt_initial_opinion_role_end",
    "payload": {
      "role": "chair",
      "chars": 555
    }
  },
  {
    "ts": "2026-01-22T18:39:07.135391",
    "event": "mdt_initial_opinion_role_start",
    "payload": {
      "role": "oncologist",
      "order": 2
    }
  },
  {
    "ts": "2026-01-22T18:39:15.929655",
    "event": "mdt_initial_opinion_role_end",
    "payload": {
      "role": "oncologist",
      "chars": 557
    }
  },
  {
    "ts": "2026-01-22T18:39:15.929723",
    "event": "mdt_initial_opinion_role_start",
    "payload": {
      "role": "radiologist",
      "order": 3
    }
  },
  {
    "ts": "2026-01-22T18:39:22.657283",
    "event": "mdt_initial_opinion_role_end",
    "payload": {
      "role": "radiologist",
      "chars": 446
    }
  },
  {
    "ts": "2026-01-22T18:39:22.657352",
    "event": "mdt_initial_opinion_role_start",
    "payload": {
      "role": "pathologist",
      "order": 4
    }
  },
  {
    "ts": "2026-01-22T18:39:28.737203",
    "event": "mdt_initial_opinion_role_end",
    "payload": {
      "role": "pathologist",
      "chars": 582
    }
  },
  {
    "ts": "2026-01-22T18:39:28.737279",
    "event": "mdt_initial_opinion_role_start",
    "payload": {
      "role": "nuclear",
      "order": 5
    }
  },
  {
    "ts": "2026-01-22T18:39:33.501246",
    "event": "mdt_initial_opinion_role_end",
    "payload": {
      "role": "nuclear",
      "chars": 480
    }
  },
  {
    "ts": "2026-01-22T18:41:14.147280",
    "event": "mdt_discussion_end",
    "payload": {
      "merged_chars": 1661
    }
  },
  {
    "ts": "2026-01-22T18:41:14.149427",
    "event": "trial_matching_start",
    "payload": {
      "trials_json_path": "files/all_trials_filtered.json"
    }
  },
  {
    "ts": "2026-01-22T18:41:21.758226",
    "event": "trial_matching_end",
    "payload": {
      "recommended": false
    }
  },
  {
    "ts": "2026-01-22T18:41:21.758245",
    "event": "final_output_start",
    "payload": {}
  },
  {
    "ts": "2026-01-22T18:41:31.624807",
    "event": "final_output_end",
    "payload": {
      "final_output_chars": 2133
    }
  }
]
```


## INITIAL EXPERT OPINIONS


## chair

```
- Continuing niraparib maintenance is appropriate given HRD-positive status [@OH2201222 | Genomics] and no evidence of recurrence per recent imaging [@2022-10-25|MR | MR].
- Monitor for ongoing thrombocytopenia; today's platelet count [@20230109|5600622 | LAB] is adequate (145), but prior interruption [@2022-04-18| | LAB] suggests need for vigilance.
- Need updated CA125 and CT imaging for formal response assessment; current plan aligns with guidelines for HRD-positive maintenance therapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].
```


## oncologist

```
- Current HRD-positive, BRCA-wildtype setting supports continuation of first-line maintenance PARP inhibitor therapy per guideline recommendation for non-BRCA mutations in HRD-positive disease [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].

- Platelet count acceptable for current maintenance therapy as per latest lab [@20230109|5600622 | LAB]; needs confirmation of CA125 trend and baseline CA125 nadir post-chemotherapy.

- Patient remains in surveillance on maintenance; ensure clear relapse monitoring as no recurrence seen on prior MRI.
```


## radiologist

```
- Lung nodules and AV fistula remain unchanged, pleural effusions improved on latest CT [@2022-09-27|CT | CT].
- No pelvic recurrence or new metastatic disease on pelvic MRI [@2022-10-25|MR | MR], consistent with the stable course recommended by guidelines for surveillance in clinical remission [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15].
- Liver hemangioma and renal cyst stable; no new visceral lesions [@2022-09-29|CT | CT].
```


## pathologist

```
- Confirm high‑grade serous carcinoma with bilateral ovarian involvement and extensive peritoneal disease.[@OH2201222 | Genomics] reports HRD positive, but IHC details (p53, WT1, etc.) are unavailable; recommend update for diagnostic certainty.
- Key biomarker: HRD positive without pathogenic BRCA1/2 mutations [@OH2201222 | Genomics], informing therapy per [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17] on maintenance strategy.
- Missing FIGO surgical stage and baseline CA125 [@actual_report_id | LAB]; complete staging is essential for current disease assessment.
```


## nuclear

```
-   No PET/CT report available for this patient; an updated PET/CT is needed to assess for metabolically active disease or recurrence.
-   Recent pelvic MRI ([@2022-10-25|MR]) shows no recurrence, but without FDG-PET, metastatic surveillance is incomplete per guideline standards [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 8].
-   CT reports ([@2022-09-27|CT], [@2022-09-29|CT]) note stable lung nodules and a hepatic hemangioma; their metabolic activity is unknown.
```


## MERGED SUMMARY (Assistant)

```
**Key Knowledge:**
- Patient is HRD-positive, BRCA-wildtype with high-grade serous ovarian carcinoma, consistent with a guideline-supported indication for first-line PARP inhibitor (niraparib) maintenance therapy.
- Imaging shows a stable anatomic course: no pelvic recurrence on MRI, stable lung nodules and AV fistula, improved pleural effusions, and stable benign findings on recent CT.
- Current labs show an adequate platelet count (145) and a CA125 of 6.45 U/mL, supporting clinical remission.
- Recent imaging (last CT: Sept 2022; last MRI: Oct 2022) shows no evidence of recurrence and supports continuing maintenance therapy.

**Controversies:**
- None explicitly noted. Consensus exists to continue maintenance therapy and proceed with updated restaging.

**Missing Info:**
1.  Updated imaging (CT chest/abdomen/pelvis) for formal response assessment, as the most recent is >3 months old.
2.  An FDG-PET/CT for comprehensive metabolic surveillance of stable lung nodules and to rule out occult disease.
3.  Complete original pathological details (IHC markers like p53, WT1) and the definitive FIGO surgical stage from the 2021 resection.
4.  The post-chemotherapy CA125 nadir and baseline CA125 from diagnosis.

**Working Plan:**
- **Continue** niraparib as first-line maintenance therapy per HRD-positive status and stable disease.
- **Order** updated CA125 (now available as 6.45), routine CT chest/abdomen/pelvis, and strongly consider an FDG-PET/CT for comprehensive restaging.
- **Monitor** platelet counts vigilantly given a history of thrombocytopenia.
- **Obtain** the original surgical pathology report to finalize IHC details and FIGO stage.
```


## INTERACTION LOG (Round × Turn)

### Round 1

#### Turn 1
- **chair → oncologist:** Agree with continued maintenance. Please obtain a current CA125 to formally confirm remission and plan timing for the next routine CT, as last major restaging was over 3 months ago [@2022-09-27|CT | CT].
- **chair → radiologist:** Thank you for the recent MR [@2022-10-25|MR | MR] and CT [@2022-09-27|CT | CT] interpretations. For the next scheduled study, please specifically comment on the pulmonary nodule [@2022-09-27|CT | CT] and assess for any subtle peritoneal disease.
- **oncologist → chair:** HRD-positive, BRCA-wildtype status supports continuing first-line maintenance PARP inhibitor per guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17], with current platelet count adequate [@20230109|5600622 | LAB].
- **radiologist → chair:** Requesting updated CT or PET/CT for January 2023 visit, as our latest imaging for chest [@2022-09-27|CT | CT] and abdomen/pelvis [@2022-09-29|CT | CT] is over three months old for this first-line maintenance therapy decision.
- **pathologist → chair:** Clarify: Our pathology basis for HRD-positive, BRCA-wt is from [@OH2201222 | Genomics], but the original IHC panel (e.g., p53, WT1) and FIGO stage from the 2021 resection are still missing. These are critical for the complete baseline record.
- **nuclear → chair:** Critical missing data: No PET/CT report available to assess metabolic disease or recurrence. An updated FDG-PET is required for complete staging and surveillance [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 8].


## FINAL REFINED PLANS (per Round)

### Round 1


## chair

```
- Continue niraparib as first-line maintenance therapy per HRD-positive, BRCA-wt status [@OH2201222 | Genomics] and guideline recommendations [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].
- Order updated CA125 now and schedule routine CT with PET/CT consideration for comprehensive restaging, as last CT was [@2022-09-27|CT | CT].
- Monitor platelet count vigilantly given prior thrombocytopenia [@20230109|5600622 | LAB]; obtain original IHC/FIGO staging from 2021 surgery.
```


## oncologist

```
- Continue PARP inhibitor maintenance therapy given HRD-positive status [@OH2201222 | Genomics] and stable disease, per guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].

- Current labs show adequate platelet count [@20230109|5600622 | LAB] and CA125 of 6.45 U/mL [@20230109|9701878 | LAB] supporting remission.

- Action: Order updated CT/PET-CT for restaging as last imaging is >3 months old [@2022-09-27|CT | CT], and request original pathology for IHC and FIGO stage.
```


## radiologist

```
- Current imaging shows stable lung nodules [@2022-09-27|CT | CT] and no pelvic recurrence [@2022-10-25|MR | MR], supporting the continuation of niraparib maintenance therapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].
- The most recent abdominal CT is from 2022-09-29 [@2022-09-29|CT | CT]; plan updated chest/abdominal CT and consider PET/CT for metabolic surveillance.
- Actively monitor for subtle peritoneal disease on the next scheduled imaging, as requested, to rule out low-volume progression.
```


## pathologist

```
- Continue niraparib maintenance per HRD‑positive, BRCA‑wildtype status [@OH2201222 | Genomics], supported by guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].
- Order updated CA125 and CT chest/abdomen/pelvis for formal response assessment; last CT was [@2022-09-27|CT | CT].
- Finalize baseline pathology record: obtain original IHC (p53/WT1) and FIGO stage from the 2021 resection report.
```


## nuclear

```
-   No PET/CT report exists for this patient; an updated FDG-PET is essential for complete metabolic staging and surveillance [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 8].
-   Recent MRI ([@2022-10-25|MR]) and CT ([@2022-09-27|CT], [@2022-09-29|CT]) show anatomic stability but do not assess functional activity.
-   Recommend a PET/CT to characterize metabolic activity of stable lung nodules noted on CT ([@2022-09-27|CT]) and evaluate for occult disease.
```


## RAW AGENT LOGS

### chair
- **User:** Give INITIAL opinion (use ONLY your system-provided patient facts).
Return up to 3 bullets, each ≤20 words.
If key data missing, say exactly what needs updating.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
For clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].
  
  **Assistant:** - Continuing niraparib maintenance is appropriate given HRD-positive status [@OH2201222 | Genomics] and no evidence of recurrence per recent imaging [@2022-10-25|MR | MR].
- Monitor for ongoing thrombocytopenia; today's platelet count [@20230109|5600622 | LAB] is adequate (145), but prior interruption [@2022-04-18| | LAB] suggests need for vigilance.
- Need updated CA125 and CT imaging for formal response assessment; current plan aligns with guidelines for HRD-positive maintenance therapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].
  
  *(2026-01-22T18:39:07.135317)*

- **User:** ROLE: chair. VISIT: 2023-01-09 09:23:13.113000
Default is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.

CONTEXT (latest):
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**
- Patient is HRD-positive, BRCA-wildtype with high-grade serous ovarian carcinoma, consistent with an indication for first-line PARP inhibitor maintenance therapy.
- Imaging shows a stable course: no pelvic recurrence on MRI, stable lung nodules and AV fistula, improved pleural effusions, and stable benign findings (liver hemangioma, renal cyst) on recent CT.
- Current platelet count (145) is adequate for continuing niraparib maintenance, though a prior interruption warrants monitoring.
- Recent imaging (MRI, CT) supports clinical remission with no evidence of recurrence.

**Controversies:**
- None explicitly noted among experts. All opinions align on continuing maintenance therapy given the HRD-positive status and stable disease.

**Missing Info:**
1.  Updated CA125 level and trend, as well as the post-chemotherapy CA125 nadir.
2.  Updated CT imaging for a formal response assessment.
3.  An updated PET/CT to fully assess for metabolically active disease.
4.  Complete pathological details (IHC markers like p53, WT1) and FIGO surgical stage.
5.  Baseline CA125 level from diagnosis.

**Working Plan:**
- Continue niraparib maintenance therapy per guideline recommendations for HRD-positive disease.
- Monitor platelet counts vigilantly.
- Obtain updated CA125 and CT imaging for response assessment.
- Consider obtaining an updated PET/CT and complete pathological staging information for comprehensive surveillance.

Allowed targets: [oncologist,radiologist,pathologist,nuclear]

EVIDENCE TAGS (if your message references evidence):
- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].

Return ONE-LINE JSON only:{"speak":"yes/no","messages":[{"target":"<role>","message":"<1-2 sentences with evidence tags if applicable>","why":"conflict|safety|missing|new"}]}
  
  **Assistant:** {"speak":"yes","messages":[{"target":"oncologist","message":"Agree with continued maintenance. Please obtain a current CA125 to formally confirm remission and plan timing for the next routine CT, as last major restaging was over 3 months ago [@2022-09-27|CT | CT].","why":"missing"},{"target":"radiologist","message":"Thank you for the recent MR [@2022-10-25|MR | MR] and CT [@2022-09-27|CT | CT] interpretations. For the next scheduled study, please specifically comment on the pulmonary nodule [@2022-09-27|CT | CT] and assess for any subtle peritoneal disease.","why":"missing"}]}
  
  *(2026-01-22T18:39:47.671304)*

- **User:** Given MDT context:
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**
- Patient is HRD-positive, BRCA-wildtype with high-grade serous ovarian carcinoma, consistent with an indication for first-line PARP inhibitor maintenance therapy.
- Imaging shows a stable course: no pelvic recurrence on MRI, stable lung nodules and AV fistula, improved pleural effusions, and stable benign findings (liver hemangioma, renal cyst) on recent CT.
- Current platelet count (145) is adequate for continuing niraparib maintenance, though a prior interruption warrants monitoring.
- Recent imaging (MRI, CT) supports clinical remission with no evidence of recurrence.

**Controversies:**
- None explicitly noted among experts. All opinions align on continuing maintenance therapy given the HRD-positive status and stable disease.

**Missing Info:**
1.  Updated CA125 level and trend, as well as the post-chemotherapy CA125 nadir.
2.  Updated CT imaging for a formal response assessment.
3.  An updated PET/CT to fully assess for metabolically active disease.
4.  Complete pathological details (IHC markers like p53, WT1) and FIGO surgical stage.
5.  Baseline CA125 level from diagnosis.

**Working Plan:**
- Continue niraparib maintenance therapy per guideline recommendations for HRD-positive disease.
- Monitor platelet counts vigilantly.
- Obtain updated CA125 and CT imaging for response assessment.
- Consider obtaining an updated PET/CT and complete pathological staging information for comprehensive surveillance.

[RECENT_DELTAS]
[R1T1 DELTA] cn_ovariancancer_v3_2025__v00000000 | Page 17], with current platelet count adequate [@20230109|5600622 | LAB]. | radiologist->chair(missing): Requesting updated CT or PET/CT for January 2023 visit, as our latest imaging for chest [@2022-09-27|CT | CT] and abdomen/pelvis [@2022-09-29|CT | CT] is over three months old for this first-line maintenance therapy decision. | pathologist->chair(unspecified): Clarify: Our pathology basis for HRD-positive, BRCA-wt is from [@OH2201222 | Genomics], but the original IHC panel (e.g., p53, WT1) and FIGO stage from the 2021 resection are still missing. These are critical for the complete baseline record. | nuclear->chair(unspecified): Critical missing data: No PET/CT report available to assess metabolic disease or recurrence. An updated FDG-PET is required for complete staging and surveillance [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 8].

DISCUSSION HISTORY (this round):
Turn 1: chair→oncologist: Agree with continued maintenance. Please obtain a current CA125 to formally confirm remission and plan timing for the next routine CT, as last major restaging was over 3 months ago [@2022-09-27|CT | CT]. | chair→radiologist: Thank you for the recent MR [@2022-10-25|MR | MR] and CT [@2022-09-27|CT | CT] interpretations. For the next scheduled study, please specifically comment on the pulmonary nodule [@2022-09-27|CT | CT] and assess for any subtle peritoneal disease. | oncologist→chair: HRD-positive, BRCA-wildtype status supports continuing first-line maintenance PARP inhibitor per guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17], with current platelet count adequate [@20230109|5600622 | LAB].

Provide FINAL refined plan based on the above context and discussions.
Up to 3 bullets, each ≤20 words.
Any factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
If discussions mentioned specific evidence, you may reference it with appropriate tags.
  
  **Assistant:** - Continue niraparib as first-line maintenance therapy per HRD-positive, BRCA-wt status [@OH2201222 | Genomics] and guideline recommendations [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].
- Order updated CA125 now and schedule routine CT with PET/CT consideration for comprehensive restaging, as last CT was [@2022-09-27|CT | CT].
- Monitor platelet count vigilantly given prior thrombocytopenia [@20230109|5600622 | LAB]; obtain original IHC/FIGO staging from 2021 surgery.
  
  *(2026-01-22T18:40:11.042530)*

- **User:** 
As the MDT chair for gynecologic oncology, you are seeing the patient at OUTPATIENT TIME: 2023-01-09 09:23:13.113000.
Based on PATIENT FACTS + MDT discussion + FINAL refined plans from all experts, determine the CURRENT best management plan for this visit.

# MDT DISCUSSION SUMMARY
**Key Knowledge:**
- Patient is HRD-positive, BRCA-wildtype with high-grade serous ovarian carcinoma, consistent with a guideline-supported indication for first-line PARP inhibitor (niraparib) maintenance therapy.
- Imaging shows a stable anatomic course: no pelvic recurrence on MRI, stable lung nodules and AV fistula, improved pleural effusions, and stable benign findings on recent CT.
- Current labs show an adequate platelet count (145) and a CA125 of 6.45 U/mL, supporting clinical remission.
- Recent imaging (last CT: Sept 2022; last MRI: Oct 2022) shows no evidence of recurrence and supports continuing maintenance therapy.

**Controversies:**
- None explicitly noted. Consensus exists to continue maintenance therapy and proceed with updated restaging.

**Missing Info:**
1.  Updated imaging (CT chest/abdomen/pelvis) for formal response assessment, as the most recent is >3 months old.
2.  An FDG-PET/CT for comprehensive metabolic surveillance of stable lung nodules and to rule out occult disease.
3.  Complete original pathological details (IHC markers like p53, WT1) and the definitive FIGO surgical stage from the 2021 resection.
4.  The post-chemotherapy CA125 nadir and baseline CA125 from diagnosis.

**Working Plan:**
- **Continue** niraparib as first-line maintenance therapy per HRD-positive status and stable disease.
- **Order** updated CA125 (now available as 6.45), routine CT chest/abdomen/pelvis, and strongly consider an FDG-PET/CT for comprehensive restaging.
- **Monitor** platelet counts vigilantly given a history of thrombocytopenia.
- **Obtain** the original surgical pathology report to finalize IHC details and FIGO stage.

# INITIAL EXPERT OPINIONS
- chair: - Continuing niraparib maintenance is appropriate given HRD-positive status [@OH2201222 | Genomics] and no evidence of recurrence per recent imaging [@2022-10-25|MR | MR].
- Monitor for ongoing thromb
- oncologist: - Current HRD-positive, BRCA-wildtype setting supports continuation of first-line maintenance PARP inhibitor therapy per guideline recommendation for non-BRCA mutations in HRD-positive disease [@guide
- radiologist: - Lung nodules and AV fistula remain unchanged, pleural effusions improved on latest CT [@2022-09-27|CT | CT].
- No pelvic recurrence or new metastatic disease on pelvic MRI [@2022-10-25|MR | MR], con
- pathologist: - Confirm high‑grade serous carcinoma with bilateral ovarian involvement and extensive peritoneal disease.[@OH2201222 | Genomics] reports HRD positive, but IHC details (p53, WT1, etc.) are unavailable
- nuclear: -   No PET/CT report available for this patient; an updated PET/CT is needed to assess for metabolically active disease or recurrence.
-   Recent pelvic MRI ([@2022-10-25|MR]) shows no recurrence, but

# DISCUSSION INTERACTIONS
Round 1: R1T1: chair→oncologist: Agree with continued maintenance. Please obtain a current CA125 to formally confirm remission and pl | R1T1: chair→radiologist: Thank you for the recent MR [@2022-10-25|MR | MR] and CT [@2022-09-27|CT | CT] interpretations. For  | R1T1: oncologist→chair: HRD-positive, BRCA-wildtype status supports continuing first-line maintenance PARP inhibitor per gui | R1T1: radiologist→chair: Requesting updated CT or PET/CT for January 2023 visit, as our latest imaging for chest [@2022-09-27 | R1T1: pathologist→chair: Clarify: Our pathology basis for HRD-positive, BRCA-wt is from [@OH2201222 | Genomics], but the orig



# FINAL REFINED PLANS (All experts, all rounds)
{
  "Round 1": {
    "chair": "- Continue niraparib as first-line maintenance therapy per HRD-positive, BRCA-wt status [@OH2201222 | Genomics] and guideline recommendations [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].\n- Order updated CA125 now and schedule routine CT with PET/CT consideration for comprehensive restaging, as last CT was [@2022-09-27|CT | CT].\n- Monitor platelet count vigilantly given prior thrombocytopenia [@20230109|5600622 | LAB]; obtain original IHC/FIGO staging from 2021 surgery.",
    "oncologist": "- Continue PARP inhibitor maintenance therapy given HRD-positive status [@OH2201222 | Genomics] and stable disease, per guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].\n\n- Current labs show adequate platelet count [@20230109|5600622 | LAB] and CA125 of 6.45 U/mL [@20230109|9701878 | LAB] supporting remission.\n\n- Action: Order updated CT/PET-CT for restaging as last imaging is >3 months old [@2022-09-27|CT | CT], and request original pathology for IHC and FIGO stage.",
    "radiologist": "- Current imaging shows stable lung nodules [@2022-09-27|CT | CT] and no pelvic recurrence [@2022-10-25|MR | MR], supporting the continuation of niraparib maintenance therapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].\n- The most recent abdominal CT is from 2022-09-29 [@2022-09-29|CT | CT]; plan updated chest/abdominal CT and consider PET/CT for metabolic surveillance.\n- Actively monitor for subtle peritoneal disease on the next scheduled imaging, as requested, to rule out low-volume progression.",
    "pathologist": "- Continue niraparib maintenance per HRD‑positive, BRCA‑wildtype status [@OH2201222 | Genomics], supported by guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].\n- Order updated CA125 and CT chest/abdomen/pelvis for formal response assessment; last CT was [@2022-09-27|CT | CT].\n- Finalize baseline pathology record: obtain original IHC (p53/WT1) and FIGO stage from the 2021 resection report.",
    "nuclear": "-   No PET/CT report exists for this patient; an updated FDG-PET is essential for complete metabolic staging and surveillance [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 8].\n-   Recent MRI ([@2022-10-25|MR]) and CT ([@2022-09-27|CT], [@2022-09-29|CT]) show anatomic stability but do not assess functional activity.\n-   Recommend a PET/CT to characterize metabolic activity of stable lung nodules noted on CT ([@2022-09-27|CT]) and evaluate for occult disease."
  }
}

# CLINICAL TRIAL RECOMMENDATION (from assistant)
Trial Recommendation:
- id: None
- name: None
- Reason: Patient is on first-line maintenance with no evidence of progression.
- Missing eligibility confirmations (0-2 items):
  - None

STRICT RULES:
- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@OH2203828|2022-04-18 | Genomics], [@2022-12-29 | MR], [@2022-12-29 | CT]). Note: Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
- If you cite guideline/PubMed evidence in Core Treatment Strategy or Change Triggers, include at least one tag in that bullet.
- If a clinical trial has been recommended by the assistant and you judge it appropriate for the patient, mention it naturally within Core Treatment Strategy or Change Triggers and cite it using [@trial | trial_id] format (e.g., [@trial | 350]).
- If experts disagree, pick the safest plan and state the key uncertainty.
- You MUST consider the MDT discussion summary and interactions above when making your decision.

# Response Format
Final Assessment:
<1–3 sentences: summarize histology/biology, current disease status, and key uncertainties>

Core Treatment Strategy:
- < ≤20 words concrete decision >
- < ≤20 words concrete decision >
- < ≤20 words concrete decision >
- < ≤20 words concrete decision >

Change Triggers:
- < ≤20 words "if X, then adjust management from A to B" >
- < ≤20 words "if X, then adjust management from A to B" >

  
  **Assistant:** Final Assessment:
HRD-positive, BRCA-wildtype high-grade serous ovarian carcinoma in first remission on maintenance niraparib. Current stable imaging [@2022-09-27|CT | CT][@2022-10-25|MR | MR] and low CA125 [@20230109|9701878 | LAB] support clinical remission. Key uncertainties include metastatic nature of stable lung nodules and lack of recent comprehensive restaging.

Core Treatment Strategy:
- Continue niraparib maintenance per HRD-positive status [@OH2201222 | Genomics] and guideline [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].
- Order updated CT chest/abdomen/pelvis now, as last staging was 3+ months ago [@2022-09-27|CT | CT].
- Consider FDG-PET/CT for metabolic assessment, especially of stable lung nodules.
- Obtain original surgical pathology for definitive IHC and FIGO stage.

Change Triggers:
- If platelet count drops below 100 [@unknown | LAB], dose-reduce or hold niraparib; reassess duration.
- If new metastasis on imaging, stop maintenance and start platinum-based chemotherapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15].
  
  *(2026-01-22T18:41:31.623106)*


### oncologist
- **User:** Give INITIAL opinion (use ONLY your system-provided patient facts).
Return up to 3 bullets, each ≤20 words.
If key data missing, say exactly what needs updating.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
For clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].
  
  **Assistant:** - Current HRD-positive, BRCA-wildtype setting supports continuation of first-line maintenance PARP inhibitor therapy per guideline recommendation for non-BRCA mutations in HRD-positive disease [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].

- Platelet count acceptable for current maintenance therapy as per latest lab [@20230109|5600622 | LAB]; needs confirmation of CA125 trend and baseline CA125 nadir post-chemotherapy.

- Patient remains in surveillance on maintenance; ensure clear relapse monitoring as no recurrence seen on prior MRI.
  
  *(2026-01-22T18:39:15.929632)*

- **User:** ROLE: oncologist. VISIT: 2023-01-09 09:23:13.113000
Default is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.

CONTEXT (latest):
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**
- Patient is HRD-positive, BRCA-wildtype with high-grade serous ovarian carcinoma, consistent with an indication for first-line PARP inhibitor maintenance therapy.
- Imaging shows a stable course: no pelvic recurrence on MRI, stable lung nodules and AV fistula, improved pleural effusions, and stable benign findings (liver hemangioma, renal cyst) on recent CT.
- Current platelet count (145) is adequate for continuing niraparib maintenance, though a prior interruption warrants monitoring.
- Recent imaging (MRI, CT) supports clinical remission with no evidence of recurrence.

**Controversies:**
- None explicitly noted among experts. All opinions align on continuing maintenance therapy given the HRD-positive status and stable disease.

**Missing Info:**
1.  Updated CA125 level and trend, as well as the post-chemotherapy CA125 nadir.
2.  Updated CT imaging for a formal response assessment.
3.  An updated PET/CT to fully assess for metabolically active disease.
4.  Complete pathological details (IHC markers like p53, WT1) and FIGO surgical stage.
5.  Baseline CA125 level from diagnosis.

**Working Plan:**
- Continue niraparib maintenance therapy per guideline recommendations for HRD-positive disease.
- Monitor platelet counts vigilantly.
- Obtain updated CA125 and CT imaging for response assessment.
- Consider obtaining an updated PET/CT and complete pathological staging information for comprehensive surveillance.

Allowed targets: [chair,radiologist,pathologist,nuclear]

EVIDENCE TAGS (if your message references evidence):
- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].

Return ONE-LINE JSON only:{"speak":"yes/no","messages":[{"target":"<role>","message":"<1-2 sentences with evidence tags if applicable>","why":"conflict|safety|missing|new"}]}
  
  **Assistant:** {"speak":"yes","messages":[{"target":"chair","message":"HRD-positive, BRCA-wildtype status supports continuing first-line maintenance PARP inhibitor per guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17], with current platelet count adequate [@20230109|5600622 | LAB].","why":"safety"}]}
  
  *(2026-01-22T18:39:52.028855)*

- **User:** Given MDT context:
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**
- Patient is HRD-positive, BRCA-wildtype with high-grade serous ovarian carcinoma, consistent with an indication for first-line PARP inhibitor maintenance therapy.
- Imaging shows a stable course: no pelvic recurrence on MRI, stable lung nodules and AV fistula, improved pleural effusions, and stable benign findings (liver hemangioma, renal cyst) on recent CT.
- Current platelet count (145) is adequate for continuing niraparib maintenance, though a prior interruption warrants monitoring.
- Recent imaging (MRI, CT) supports clinical remission with no evidence of recurrence.

**Controversies:**
- None explicitly noted among experts. All opinions align on continuing maintenance therapy given the HRD-positive status and stable disease.

**Missing Info:**
1.  Updated CA125 level and trend, as well as the post-chemotherapy CA125 nadir.
2.  Updated CT imaging for a formal response assessment.
3.  An updated PET/CT to fully assess for metabolically active disease.
4.  Complete pathological details (IHC markers like p53, WT1) and FIGO surgical stage.
5.  Baseline CA125 level from diagnosis.

**Working Plan:**
- Continue niraparib maintenance therapy per guideline recommendations for HRD-positive disease.
- Monitor platelet counts vigilantly.
- Obtain updated CA125 and CT imaging for response assessment.
- Consider obtaining an updated PET/CT and complete pathological staging information for comprehensive surveillance.

[RECENT_DELTAS]
[R1T1 DELTA] cn_ovariancancer_v3_2025__v00000000 | Page 17], with current platelet count adequate [@20230109|5600622 | LAB]. | radiologist->chair(missing): Requesting updated CT or PET/CT for January 2023 visit, as our latest imaging for chest [@2022-09-27|CT | CT] and abdomen/pelvis [@2022-09-29|CT | CT] is over three months old for this first-line maintenance therapy decision. | pathologist->chair(unspecified): Clarify: Our pathology basis for HRD-positive, BRCA-wt is from [@OH2201222 | Genomics], but the original IHC panel (e.g., p53, WT1) and FIGO stage from the 2021 resection are still missing. These are critical for the complete baseline record. | nuclear->chair(unspecified): Critical missing data: No PET/CT report available to assess metabolic disease or recurrence. An updated FDG-PET is required for complete staging and surveillance [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 8].

DISCUSSION HISTORY (this round):
Turn 1: chair→oncologist: Agree with continued maintenance. Please obtain a current CA125 to formally confirm remission and plan timing for the next routine CT, as last major restaging was over 3 months ago [@2022-09-27|CT | CT]. | chair→radiologist: Thank you for the recent MR [@2022-10-25|MR | MR] and CT [@2022-09-27|CT | CT] interpretations. For the next scheduled study, please specifically comment on the pulmonary nodule [@2022-09-27|CT | CT] and assess for any subtle peritoneal disease. | oncologist→chair: HRD-positive, BRCA-wildtype status supports continuing first-line maintenance PARP inhibitor per guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17], with current platelet count adequate [@20230109|5600622 | LAB].

Provide FINAL refined plan based on the above context and discussions.
Up to 3 bullets, each ≤20 words.
Any factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
If discussions mentioned specific evidence, you may reference it with appropriate tags.
  
  **Assistant:** - Continue PARP inhibitor maintenance therapy given HRD-positive status [@OH2201222 | Genomics] and stable disease, per guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].

- Current labs show adequate platelet count [@20230109|5600622 | LAB] and CA125 of 6.45 U/mL [@20230109|9701878 | LAB] supporting remission.

- Action: Order updated CT/PET-CT for restaging as last imaging is >3 months old [@2022-09-27|CT | CT], and request original pathology for IHC and FIGO stage.
  
  *(2026-01-22T18:40:38.027042)*


### radiologist
- **User:** Give INITIAL opinion (use ONLY your system-provided patient facts).
Return up to 3 bullets, each ≤20 words.
If key data missing, say exactly what needs updating.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
For clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].
  
  **Assistant:** - Lung nodules and AV fistula remain unchanged, pleural effusions improved on latest CT [@2022-09-27|CT | CT].
- No pelvic recurrence or new metastatic disease on pelvic MRI [@2022-10-25|MR | MR], consistent with the stable course recommended by guidelines for surveillance in clinical remission [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15].
- Liver hemangioma and renal cyst stable; no new visceral lesions [@2022-09-29|CT | CT].
  
  *(2026-01-22T18:39:22.657256)*

- **User:** ROLE: radiologist. VISIT: 2023-01-09 09:23:13.113000
Default is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.

CONTEXT (latest):
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**
- Patient is HRD-positive, BRCA-wildtype with high-grade serous ovarian carcinoma, consistent with an indication for first-line PARP inhibitor maintenance therapy.
- Imaging shows a stable course: no pelvic recurrence on MRI, stable lung nodules and AV fistula, improved pleural effusions, and stable benign findings (liver hemangioma, renal cyst) on recent CT.
- Current platelet count (145) is adequate for continuing niraparib maintenance, though a prior interruption warrants monitoring.
- Recent imaging (MRI, CT) supports clinical remission with no evidence of recurrence.

**Controversies:**
- None explicitly noted among experts. All opinions align on continuing maintenance therapy given the HRD-positive status and stable disease.

**Missing Info:**
1.  Updated CA125 level and trend, as well as the post-chemotherapy CA125 nadir.
2.  Updated CT imaging for a formal response assessment.
3.  An updated PET/CT to fully assess for metabolically active disease.
4.  Complete pathological details (IHC markers like p53, WT1) and FIGO surgical stage.
5.  Baseline CA125 level from diagnosis.

**Working Plan:**
- Continue niraparib maintenance therapy per guideline recommendations for HRD-positive disease.
- Monitor platelet counts vigilantly.
- Obtain updated CA125 and CT imaging for response assessment.
- Consider obtaining an updated PET/CT and complete pathological staging information for comprehensive surveillance.

Allowed targets: [chair,oncologist,pathologist,nuclear]

EVIDENCE TAGS (if your message references evidence):
- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].

Return ONE-LINE JSON only:{"speak":"yes/no","messages":[{"target":"<role>","message":"<1-2 sentences with evidence tags if applicable>","why":"conflict|safety|missing|new"}]}
  
  **Assistant:** {"speak":"yes","messages":[{"target":"chair","message":"Requesting updated CT or PET/CT for January 2023 visit, as our latest imaging for chest [@2022-09-27|CT | CT] and abdomen/pelvis [@2022-09-29|CT | CT] is over three months old for this first-line maintenance therapy decision.","why":"missing"}]}
  
  *(2026-01-22T18:39:56.952999)*

- **User:** Given MDT context:
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**
- Patient is HRD-positive, BRCA-wildtype with high-grade serous ovarian carcinoma, consistent with an indication for first-line PARP inhibitor maintenance therapy.
- Imaging shows a stable course: no pelvic recurrence on MRI, stable lung nodules and AV fistula, improved pleural effusions, and stable benign findings (liver hemangioma, renal cyst) on recent CT.
- Current platelet count (145) is adequate for continuing niraparib maintenance, though a prior interruption warrants monitoring.
- Recent imaging (MRI, CT) supports clinical remission with no evidence of recurrence.

**Controversies:**
- None explicitly noted among experts. All opinions align on continuing maintenance therapy given the HRD-positive status and stable disease.

**Missing Info:**
1.  Updated CA125 level and trend, as well as the post-chemotherapy CA125 nadir.
2.  Updated CT imaging for a formal response assessment.
3.  An updated PET/CT to fully assess for metabolically active disease.
4.  Complete pathological details (IHC markers like p53, WT1) and FIGO surgical stage.
5.  Baseline CA125 level from diagnosis.

**Working Plan:**
- Continue niraparib maintenance therapy per guideline recommendations for HRD-positive disease.
- Monitor platelet counts vigilantly.
- Obtain updated CA125 and CT imaging for response assessment.
- Consider obtaining an updated PET/CT and complete pathological staging information for comprehensive surveillance.

[RECENT_DELTAS]
[R1T1 DELTA] cn_ovariancancer_v3_2025__v00000000 | Page 17], with current platelet count adequate [@20230109|5600622 | LAB]. | radiologist->chair(missing): Requesting updated CT or PET/CT for January 2023 visit, as our latest imaging for chest [@2022-09-27|CT | CT] and abdomen/pelvis [@2022-09-29|CT | CT] is over three months old for this first-line maintenance therapy decision. | pathologist->chair(unspecified): Clarify: Our pathology basis for HRD-positive, BRCA-wt is from [@OH2201222 | Genomics], but the original IHC panel (e.g., p53, WT1) and FIGO stage from the 2021 resection are still missing. These are critical for the complete baseline record. | nuclear->chair(unspecified): Critical missing data: No PET/CT report available to assess metabolic disease or recurrence. An updated FDG-PET is required for complete staging and surveillance [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 8].

DISCUSSION HISTORY (this round):
Turn 1: chair→oncologist: Agree with continued maintenance. Please obtain a current CA125 to formally confirm remission and plan timing for the next routine CT, as last major restaging was over 3 months ago [@2022-09-27|CT | CT]. | chair→radiologist: Thank you for the recent MR [@2022-10-25|MR | MR] and CT [@2022-09-27|CT | CT] interpretations. For the next scheduled study, please specifically comment on the pulmonary nodule [@2022-09-27|CT | CT] and assess for any subtle peritoneal disease. | oncologist→chair: HRD-positive, BRCA-wildtype status supports continuing first-line maintenance PARP inhibitor per guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17], with current platelet count adequate [@20230109|5600622 | LAB].

Provide FINAL refined plan based on the above context and discussions.
Up to 3 bullets, each ≤20 words.
Any factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
If discussions mentioned specific evidence, you may reference it with appropriate tags.
  
  **Assistant:** - Current imaging shows stable lung nodules [@2022-09-27|CT | CT] and no pelvic recurrence [@2022-10-25|MR | MR], supporting the continuation of niraparib maintenance therapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].
- The most recent abdominal CT is from 2022-09-29 [@2022-09-29|CT | CT]; plan updated chest/abdominal CT and consider PET/CT for metabolic surveillance.
- Actively monitor for subtle peritoneal disease on the next scheduled imaging, as requested, to rule out low-volume progression.
  
  *(2026-01-22T18:40:51.461015)*


### pathologist
- **User:** Give INITIAL opinion (use ONLY your system-provided patient facts).
Return up to 3 bullets, each ≤20 words.
If key data missing, say exactly what needs updating.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
For clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].
  
  **Assistant:** - Confirm high‑grade serous carcinoma with bilateral ovarian involvement and extensive peritoneal disease.[@OH2201222 | Genomics] reports HRD positive, but IHC details (p53, WT1, etc.) are unavailable; recommend update for diagnostic certainty.
- Key biomarker: HRD positive without pathogenic BRCA1/2 mutations [@OH2201222 | Genomics], informing therapy per [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17] on maintenance strategy.
- Missing FIGO surgical stage and baseline CA125 [@actual_report_id | LAB]; complete staging is essential for current disease assessment.
  
  *(2026-01-22T18:39:28.737185)*

- **User:** ROLE: pathologist. VISIT: 2023-01-09 09:23:13.113000
Default is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.

CONTEXT (latest):
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**
- Patient is HRD-positive, BRCA-wildtype with high-grade serous ovarian carcinoma, consistent with an indication for first-line PARP inhibitor maintenance therapy.
- Imaging shows a stable course: no pelvic recurrence on MRI, stable lung nodules and AV fistula, improved pleural effusions, and stable benign findings (liver hemangioma, renal cyst) on recent CT.
- Current platelet count (145) is adequate for continuing niraparib maintenance, though a prior interruption warrants monitoring.
- Recent imaging (MRI, CT) supports clinical remission with no evidence of recurrence.

**Controversies:**
- None explicitly noted among experts. All opinions align on continuing maintenance therapy given the HRD-positive status and stable disease.

**Missing Info:**
1.  Updated CA125 level and trend, as well as the post-chemotherapy CA125 nadir.
2.  Updated CT imaging for a formal response assessment.
3.  An updated PET/CT to fully assess for metabolically active disease.
4.  Complete pathological details (IHC markers like p53, WT1) and FIGO surgical stage.
5.  Baseline CA125 level from diagnosis.

**Working Plan:**
- Continue niraparib maintenance therapy per guideline recommendations for HRD-positive disease.
- Monitor platelet counts vigilantly.
- Obtain updated CA125 and CT imaging for response assessment.
- Consider obtaining an updated PET/CT and complete pathological staging information for comprehensive surveillance.

Allowed targets: [chair,oncologist,radiologist,nuclear]

EVIDENCE TAGS (if your message references evidence):
- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].

Return ONE-LINE JSON only:{"speak":"yes/no","messages":[{"target":"<role>","message":"<1-2 sentences with evidence tags if applicable>","why":"conflict|safety|missing|new"}]}
  
  **Assistant:** {"speak":"yes","messages":[{"target":"chair","message":"Clarify: Our pathology basis for HRD-positive, BRCA-wt is from [@OH2201222 | Genomics], but the original IHC panel (e.g., p53, WT1) and FIGO stage from the 2021 resection are still missing. These are critical for the complete baseline record.","why":"missing-critical"}]}
  
  *(2026-01-22T18:40:01.875312)*

- **User:** Given MDT context:
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**
- Patient is HRD-positive, BRCA-wildtype with high-grade serous ovarian carcinoma, consistent with an indication for first-line PARP inhibitor maintenance therapy.
- Imaging shows a stable course: no pelvic recurrence on MRI, stable lung nodules and AV fistula, improved pleural effusions, and stable benign findings (liver hemangioma, renal cyst) on recent CT.
- Current platelet count (145) is adequate for continuing niraparib maintenance, though a prior interruption warrants monitoring.
- Recent imaging (MRI, CT) supports clinical remission with no evidence of recurrence.

**Controversies:**
- None explicitly noted among experts. All opinions align on continuing maintenance therapy given the HRD-positive status and stable disease.

**Missing Info:**
1.  Updated CA125 level and trend, as well as the post-chemotherapy CA125 nadir.
2.  Updated CT imaging for a formal response assessment.
3.  An updated PET/CT to fully assess for metabolically active disease.
4.  Complete pathological details (IHC markers like p53, WT1) and FIGO surgical stage.
5.  Baseline CA125 level from diagnosis.

**Working Plan:**
- Continue niraparib maintenance therapy per guideline recommendations for HRD-positive disease.
- Monitor platelet counts vigilantly.
- Obtain updated CA125 and CT imaging for response assessment.
- Consider obtaining an updated PET/CT and complete pathological staging information for comprehensive surveillance.

[RECENT_DELTAS]
[R1T1 DELTA] cn_ovariancancer_v3_2025__v00000000 | Page 17], with current platelet count adequate [@20230109|5600622 | LAB]. | radiologist->chair(missing): Requesting updated CT or PET/CT for January 2023 visit, as our latest imaging for chest [@2022-09-27|CT | CT] and abdomen/pelvis [@2022-09-29|CT | CT] is over three months old for this first-line maintenance therapy decision. | pathologist->chair(unspecified): Clarify: Our pathology basis for HRD-positive, BRCA-wt is from [@OH2201222 | Genomics], but the original IHC panel (e.g., p53, WT1) and FIGO stage from the 2021 resection are still missing. These are critical for the complete baseline record. | nuclear->chair(unspecified): Critical missing data: No PET/CT report available to assess metabolic disease or recurrence. An updated FDG-PET is required for complete staging and surveillance [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 8].

DISCUSSION HISTORY (this round):
Turn 1: chair→oncologist: Agree with continued maintenance. Please obtain a current CA125 to formally confirm remission and plan timing for the next routine CT, as last major restaging was over 3 months ago [@2022-09-27|CT | CT]. | chair→radiologist: Thank you for the recent MR [@2022-10-25|MR | MR] and CT [@2022-09-27|CT | CT] interpretations. For the next scheduled study, please specifically comment on the pulmonary nodule [@2022-09-27|CT | CT] and assess for any subtle peritoneal disease. | oncologist→chair: HRD-positive, BRCA-wildtype status supports continuing first-line maintenance PARP inhibitor per guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17], with current platelet count adequate [@20230109|5600622 | LAB].

Provide FINAL refined plan based on the above context and discussions.
Up to 3 bullets, each ≤20 words.
Any factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
If discussions mentioned specific evidence, you may reference it with appropriate tags.
  
  **Assistant:** - Continue niraparib maintenance per HRD‑positive, BRCA‑wildtype status [@OH2201222 | Genomics], supported by guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].
- Order updated CA125 and CT chest/abdomen/pelvis for formal response assessment; last CT was [@2022-09-27|CT | CT].
- Finalize baseline pathology record: obtain original IHC (p53/WT1) and FIGO stage from the 2021 resection report.
  
  *(2026-01-22T18:40:56.502907)*


### nuclear
- **User:** Give INITIAL opinion (use ONLY your system-provided patient facts).
Return up to 3 bullets, each ≤20 words.
If key data missing, say exactly what needs updating.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
For clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].
  
  **Assistant:** -   No PET/CT report available for this patient; an updated PET/CT is needed to assess for metabolically active disease or recurrence.
-   Recent pelvic MRI ([@2022-10-25|MR]) shows no recurrence, but without FDG-PET, metastatic surveillance is incomplete per guideline standards [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 8].
-   CT reports ([@2022-09-27|CT], [@2022-09-29|CT]) note stable lung nodules and a hepatic hemangioma; their metabolic activity is unknown.
  
  *(2026-01-22T18:39:33.501233)*

- **User:** ROLE: nuclear. VISIT: 2023-01-09 09:23:13.113000
Default is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.

CONTEXT (latest):
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**
- Patient is HRD-positive, BRCA-wildtype with high-grade serous ovarian carcinoma, consistent with an indication for first-line PARP inhibitor maintenance therapy.
- Imaging shows a stable course: no pelvic recurrence on MRI, stable lung nodules and AV fistula, improved pleural effusions, and stable benign findings (liver hemangioma, renal cyst) on recent CT.
- Current platelet count (145) is adequate for continuing niraparib maintenance, though a prior interruption warrants monitoring.
- Recent imaging (MRI, CT) supports clinical remission with no evidence of recurrence.

**Controversies:**
- None explicitly noted among experts. All opinions align on continuing maintenance therapy given the HRD-positive status and stable disease.

**Missing Info:**
1.  Updated CA125 level and trend, as well as the post-chemotherapy CA125 nadir.
2.  Updated CT imaging for a formal response assessment.
3.  An updated PET/CT to fully assess for metabolically active disease.
4.  Complete pathological details (IHC markers like p53, WT1) and FIGO surgical stage.
5.  Baseline CA125 level from diagnosis.

**Working Plan:**
- Continue niraparib maintenance therapy per guideline recommendations for HRD-positive disease.
- Monitor platelet counts vigilantly.
- Obtain updated CA125 and CT imaging for response assessment.
- Consider obtaining an updated PET/CT and complete pathological staging information for comprehensive surveillance.

Allowed targets: [chair,oncologist,radiologist,pathologist]

EVIDENCE TAGS (if your message references evidence):
- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].

Return ONE-LINE JSON only:{"speak":"yes/no","messages":[{"target":"<role>","message":"<1-2 sentences with evidence tags if applicable>","why":"conflict|safety|missing|new"}]}
  
  **Assistant:** {"speak":"yes","messages":[{"target":"chair","message":"Critical missing data: No PET/CT report available to assess metabolic disease or recurrence. An updated FDG-PET is required for complete staging and surveillance [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 8].","why":"missing-critical"}]}
  
  *(2026-01-22T18:40:05.907010)*

- **User:** Given MDT context:
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**
- Patient is HRD-positive, BRCA-wildtype with high-grade serous ovarian carcinoma, consistent with an indication for first-line PARP inhibitor maintenance therapy.
- Imaging shows a stable course: no pelvic recurrence on MRI, stable lung nodules and AV fistula, improved pleural effusions, and stable benign findings (liver hemangioma, renal cyst) on recent CT.
- Current platelet count (145) is adequate for continuing niraparib maintenance, though a prior interruption warrants monitoring.
- Recent imaging (MRI, CT) supports clinical remission with no evidence of recurrence.

**Controversies:**
- None explicitly noted among experts. All opinions align on continuing maintenance therapy given the HRD-positive status and stable disease.

**Missing Info:**
1.  Updated CA125 level and trend, as well as the post-chemotherapy CA125 nadir.
2.  Updated CT imaging for a formal response assessment.
3.  An updated PET/CT to fully assess for metabolically active disease.
4.  Complete pathological details (IHC markers like p53, WT1) and FIGO surgical stage.
5.  Baseline CA125 level from diagnosis.

**Working Plan:**
- Continue niraparib maintenance therapy per guideline recommendations for HRD-positive disease.
- Monitor platelet counts vigilantly.
- Obtain updated CA125 and CT imaging for response assessment.
- Consider obtaining an updated PET/CT and complete pathological staging information for comprehensive surveillance.

[RECENT_DELTAS]
[R1T1 DELTA] cn_ovariancancer_v3_2025__v00000000 | Page 17], with current platelet count adequate [@20230109|5600622 | LAB]. | radiologist->chair(missing): Requesting updated CT or PET/CT for January 2023 visit, as our latest imaging for chest [@2022-09-27|CT | CT] and abdomen/pelvis [@2022-09-29|CT | CT] is over three months old for this first-line maintenance therapy decision. | pathologist->chair(unspecified): Clarify: Our pathology basis for HRD-positive, BRCA-wt is from [@OH2201222 | Genomics], but the original IHC panel (e.g., p53, WT1) and FIGO stage from the 2021 resection are still missing. These are critical for the complete baseline record. | nuclear->chair(unspecified): Critical missing data: No PET/CT report available to assess metabolic disease or recurrence. An updated FDG-PET is required for complete staging and surveillance [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 8].

DISCUSSION HISTORY (this round):
Turn 1: chair→oncologist: Agree with continued maintenance. Please obtain a current CA125 to formally confirm remission and plan timing for the next routine CT, as last major restaging was over 3 months ago [@2022-09-27|CT | CT]. | chair→radiologist: Thank you for the recent MR [@2022-10-25|MR | MR] and CT [@2022-09-27|CT | CT] interpretations. For the next scheduled study, please specifically comment on the pulmonary nodule [@2022-09-27|CT | CT] and assess for any subtle peritoneal disease. | oncologist→chair: HRD-positive, BRCA-wildtype status supports continuing first-line maintenance PARP inhibitor per guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17], with current platelet count adequate [@20230109|5600622 | LAB].

Provide FINAL refined plan based on the above context and discussions.
Up to 3 bullets, each ≤20 words.
Any factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
If discussions mentioned specific evidence, you may reference it with appropriate tags.
  
  **Assistant:** -   No PET/CT report exists for this patient; an updated FDG-PET is essential for complete metabolic staging and surveillance [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 8].
-   Recent MRI ([@2022-10-25|MR]) and CT ([@2022-09-27|CT], [@2022-09-29|CT]) show anatomic stability but do not assess functional activity.
-   Recommend a PET/CT to characterize metabolic activity of stable lung nodules noted on CT ([@2022-09-27|CT]) and evaluate for occult disease.
  
  *(2026-01-22T18:41:02.419501)*


### assistant
- **User:** Summarize expert opinions concisely for MDT.
{"chair":"- Continuing niraparib maintenance is appropriate given HRD-positive status [@OH2201222 | Genomics] and no evidence of recurrence per recent imaging [@2022-10-25|MR | MR].\n- Monitor for ongoing thrombocytopenia; today's platelet count [@20230109|5600622 | LAB] is adequate (145), but prior interruption [@2022-04-18| | LAB] suggests need for vigilance.\n- Need updated CA125 and CT imaging for formal response assessment; current plan aligns with guidelines for HRD-positive maintenance therapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].","oncologist":"- Current HRD-positive, BRCA-wildtype setting supports continuation of first-line maintenance PARP inhibitor therapy per guideline recommendation for non-BRCA mutations in HRD-positive disease [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].\n\n- Platelet count acceptable for current maintenance therapy as per latest lab [@20230109|5600622 | LAB]; needs confirmation of CA125 trend and baseline CA125 nadir post-chemotherapy.\n\n- Patient remains in surveillance on maintenance; ensure clear relapse monitoring as no recurrence seen on prior MRI.","radiologist":"- Lung nodules and AV fistula remain unchanged, pleural effusions improved on latest CT [@2022-09-27|CT | CT].\n- No pelvic recurrence or new metastatic disease on pelvic MRI [@2022-10-25|MR | MR], consistent with the stable course recommended by guidelines for surveillance in clinical remission [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15].\n- Liver hemangioma and renal cyst stable; no new visceral lesions [@2022-09-29|CT | CT].","pathologist":"- Confirm high‑grade serous carcinoma with bilateral ovarian involvement and extensive peritoneal disease.[@OH2201222 | Genomics] reports HRD positive, but IHC details (p53, WT1, etc.) are unavailable; recommend update for diagnostic certainty.\n- Key biomarker: HRD positive without pathogenic BRCA1/2 mutations [@OH2201222 | Genomics], informing therapy per [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17] on maintenance strategy.\n- Missing FIGO surgical stage and baseline CA125 [@actual_report_id | LAB]; complete staging is essential for current disease assessment.","nuclear":"-   No PET/CT report available for this patient; an updated PET/CT is needed to assess for metabolically active disease or recurrence.\n-   Recent pelvic MRI ([@2022-10-25|MR]) shows no recurrence, but without FDG-PET, metastatic surveillance is incomplete per guideline standards [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 8].\n-   CT reports ([@2022-09-27|CT], [@2022-09-29|CT]) note stable lung nodules and a hepatic hemangioma; their metabolic activity is unknown."}

Output:
Key Knowledge:
- ...
Controversies:
- ...
Missing Info:
- ...
Working Plan:
- ...
  
  **Assistant:** **Key Knowledge:**
- Patient is HRD-positive, BRCA-wildtype with high-grade serous ovarian carcinoma, consistent with an indication for first-line PARP inhibitor maintenance therapy.
- Imaging shows a stable course: no pelvic recurrence on MRI, stable lung nodules and AV fistula, improved pleural effusions, and stable benign findings (liver hemangioma, renal cyst) on recent CT.
- Current platelet count (145) is adequate for continuing niraparib maintenance, though a prior interruption warrants monitoring.
- Recent imaging (MRI, CT) supports clinical remission with no evidence of recurrence.

**Controversies:**
- None explicitly noted among experts. All opinions align on continuing maintenance therapy given the HRD-positive status and stable disease.

**Missing Info:**
1.  Updated CA125 level and trend, as well as the post-chemotherapy CA125 nadir.
2.  Updated CT imaging for a formal response assessment.
3.  An updated PET/CT to fully assess for metabolically active disease.
4.  Complete pathological details (IHC markers like p53, WT1) and FIGO surgical stage.
5.  Baseline CA125 level from diagnosis.

**Working Plan:**
- Continue niraparib maintenance therapy per guideline recommendations for HRD-positive disease.
- Monitor platelet counts vigilantly.
- Obtain updated CA125 and CT imaging for response assessment.
- Consider obtaining an updated PET/CT and complete pathological staging information for comprehensive surveillance.
  
  *(2026-01-22T18:39:41.181350)*

- **User:** You are MDT assistant. Update MDT GLOBAL structured memory by integrating ROUND FINAL plans. Keep the same output format with: Key Knowledge / Controversies / Missing Info / Working Plan.

CURRENT_MDT_GLOBAL_KNOWLEDGE:
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**
- Patient is HRD-positive, BRCA-wildtype with high-grade serous ovarian carcinoma, consistent with an indication for first-line PARP inhibitor maintenance therapy.
- Imaging shows a stable course: no pelvic recurrence on MRI, stable lung nodules and AV fistula, improved pleural effusions, and stable benign findings (liver hemangioma, renal cyst) on recent CT.
- Current platelet count (145) is adequate for continuing niraparib maintenance, though a prior interruption warrants monitoring.
- Recent imaging (MRI, CT) supports clinical remission with no evidence of recurrence.

**Controversies:**
- None explicitly noted among experts. All opinions align on continuing maintenance therapy given the HRD-positive status and stable disease.

**Missing Info:**
1.  Updated CA125 level and trend, as well as the post-chemotherapy CA125 nadir.
2.  Updated CT imaging for a formal response assessment.
3.  An updated PET/CT to fully assess for metabolically active disease.
4.  Complete pathological details (IHC markers like p53, WT1) and FIGO surgical stage.
5.  Baseline CA125 level from diagnosis.

**Working Plan:**
- Continue niraparib maintenance therapy per guideline recommendations for HRD-positive disease.
- Monitor platelet counts vigilantly.
- Obtain updated CA125 and CT imaging for response assessment.
- Consider obtaining an updated PET/CT and complete pathological staging information for comprehensive surveillance.

ROUND_1_FINAL_PLANS_JSON:
{"chair":"- Continue niraparib as first-line maintenance therapy per HRD-positive, BRCA-wt status [@OH2201222 | Genomics] and guideline recommendations [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].\n- Order updated CA125 now and schedule routine CT with PET/CT consideration for comprehensive restaging, as last CT was [@2022-09-27|CT | CT].\n- Monitor platelet count vigilantly given prior thrombocytopenia [@20230109|5600622 | LAB]; obtain original IHC/FIGO staging from 2021 surgery.","oncologist":"- Continue PARP inhibitor maintenance therapy given HRD-positive status [@OH2201222 | Genomics] and stable disease, per guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].\n\n- Current labs show adequate platelet count [@20230109|5600622 | LAB] and CA125 of 6.45 U/mL [@20230109|9701878 | LAB] supporting remission.\n\n- Action: Order updated CT/PET-CT for restaging as last imaging is >3 months old [@2022-09-27|CT | CT], and request original pathology for IHC and FIGO stage.","radiologist":"- Current imaging shows stable lung nodules [@2022-09-27|CT | CT] and no pelvic recurrence [@2022-10-25|MR | MR], supporting the continuation of niraparib maintenance therapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].\n- The most recent abdominal CT is from 2022-09-29 [@2022-09-29|CT | CT]; plan updated chest/abdominal CT and consider PET/CT for metabolic surveillance.\n- Actively monitor for subtle peritoneal disease on the next scheduled imaging, as requested, to rule out low-volume progression.","pathologist":"- Continue niraparib maintenance per HRD‑positive, BRCA‑wildtype status [@OH2201222 | Genomics], supported by guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].\n- Order updated CA125 and CT chest/abdomen/pelvis for formal response assessment; last CT was [@2022-09-27|CT | CT].\n- Finalize baseline pathology record: obtain original IHC (p53/WT1) and FIGO stage from the 2021 resection report.","nuclear":"-   No PET/CT report exists for this patient; an updated FDG-PET is essential for complete metabolic staging and surveillance [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 8].\n-   Recent MRI ([@2022-10-25|MR]) and CT ([@2022-09-27|CT], [@2022-09-29|CT]) show anatomic stability but do not assess functional activity.\n-   Recommend a PET/CT to characterize metabolic activity of stable lung nodules noted on CT ([@2022-09-27|CT]) and evaluate for occult disease."}
  
  **Assistant:** **Key Knowledge:**
- Patient is HRD-positive, BRCA-wildtype with high-grade serous ovarian carcinoma, consistent with a guideline-supported indication for first-line PARP inhibitor (niraparib) maintenance therapy.
- Imaging shows a stable anatomic course: no pelvic recurrence on MRI, stable lung nodules and AV fistula, improved pleural effusions, and stable benign findings on recent CT.
- Current labs show an adequate platelet count (145) and a CA125 of 6.45 U/mL, supporting clinical remission.
- Recent imaging (last CT: Sept 2022; last MRI: Oct 2022) shows no evidence of recurrence and supports continuing maintenance therapy.

**Controversies:**
- None explicitly noted. Consensus exists to continue maintenance therapy and proceed with updated restaging.

**Missing Info:**
1.  Updated imaging (CT chest/abdomen/pelvis) for formal response assessment, as the most recent is >3 months old.
2.  An FDG-PET/CT for comprehensive metabolic surveillance of stable lung nodules and to rule out occult disease.
3.  Complete original pathological details (IHC markers like p53, WT1) and the definitive FIGO surgical stage from the 2021 resection.
4.  The post-chemotherapy CA125 nadir and baseline CA125 from diagnosis.

**Working Plan:**
- **Continue** niraparib as first-line maintenance therapy per HRD-positive status and stable disease.
- **Order** updated CA125 (now available as 6.45), routine CT chest/abdomen/pelvis, and strongly consider an FDG-PET/CT for comprehensive restaging.
- **Monitor** platelet counts vigilantly given a history of thrombocytopenia.
- **Obtain** the original surgical pathology report to finalize IHC details and FIGO stage.
  
  *(2026-01-22T18:41:14.146678)*


### trial_selector
- **User:** You are an MDT assistant for gynecologic oncology clinical trial matching.

CRITICAL BEHAVIOR:
- You MUST NOT ask the user any questions.
- You MUST NOT request additional information.
- You MUST NOT output anything except the required template.
- Use ONLY the provided PATIENT CASE text and AVAILABLE TRIALS list.
- If eligibility is unclear due to missing key facts, you MUST output None.

PATIENT CASE (facts only; do not infer):
# ORIGINAL CASE JSON
{"CASE_CORE":{"ADJUVANT_TREATMENT":{"cycles_or_courses":"6","given":"Yes","regimens":["TP"]},"BIOMARKERS":{"AFP":"Unknown","CA125":"Unknown","HER2":"Unknown","MSI":"Unknown","PDL1_CPS":"Unknown","TMB":"Unknown"},"BRCA1":"Unknown","BRCA2":"Unknown","CURRENT_STATUS":"On maintenance niraparib; ECOG 1; recent imaging without pelvic recurrence.","DIAGNOSIS":{"components":["Adenocarcinoma","High-grade serous carcinoma"],"histology":"High-grade serous carcinoma","laterality":"Bilateral","primary":"Ovarian cancer","site":"Ovary"},"ECOG":"1","GENOMICS":{"HRD_STATUS":{"method":"Unknown","result":"Positive","score":"Unknown"},"alterations":[],"testing_date":"Unknown","testing_performed":"Yes","testing_platform":"Unknown"},"HRD":"Positive","INITIAL_TREATMENT":"Yes","LINE_OF_THERAPY":[{"concurrent_bevacizumab":"No","cycles_completed":"1","cycles_planned":"Unknown","discontinuation":{"detail":"Switched to TP chemotherapy","reason":"Other"},"end_date":"2021-09-07","in_clinical_trial":"No","intent":"First_line","line":"1L","pfs_days":"41","regimen":"顺铂50mg腹腔化疗","response_assessment":{"best_response":"Unknown","ca125_response":"Unknown","response_criteria":"Unknown","response_date":"Unknown"},"start_date":"2021-09-06"},{"concurrent_bevacizumab":"No","cycles_completed":"6","cycles_planned":"6","discontinuation":{"detail":"Completed 6 cycles","reason":"Completed"},"end_date":"2022-03-22","in_clinical_trial":"No","intent":"First_line","line":"1L","pfs_days":"Unknown","regimen":"TP","response_assessment":{"best_response":"Unknown","ca125_response":"Unknown","response_criteria":"Unknown","response_date":"Unknown"},"start_date":"2021-10-18"},{"concurrent_bevacizumab":"No","cycles_completed":"Unknown","cycles_planned":"Unknown","discontinuation":{"detail":"Temporarily stopped due to adverse reactions and low platelets; restarted 2022-05-23; held 3 weeks around hernia repair; currently continuing","reason":"Other"},"end_date":"Unknown","in_clinical_trial":"No","intent":"Maintenance","line":"1L","pfs_days":"Unknown","regimen":"尼拉帕利","response_assessment":{"best_response":"Unknown","ca125_response":"Unknown","response_criteria":"Unknown","response_date":"Unknown"},"start_date":"2022-04-Unknown"}],"MAINTENANCE":"Yes","MAINTENANCE_DETAIL":{"end_date":"Unknown","given":"Yes","regimens":["尼拉帕利"],"start_date":"2022-04-Unknown"},"NEOADJUVANT":"Unknown","PFI_days":"Unknown","PLATINUM_HISTORY":[{"PFI_days":"Unknown","end_date":"2022-03-22","evidence":"TP chemotherapy 6 cycles after primary surgery; no explicit relapse documented.","evidence_type":"Unknown","first_relapse_date":"Unknown","line":"1L","start_date":"2021-10-18","status":"Unknown"}],"PLATINUM_PFI_CURRENT":"Unknown","PLATINUM_STATUS":"Unknown","PLATINUM_STATUS_CURRENT":"Unknown","RELAPSE":"No","RELAPSE_DATE":{"date":"Unknown","evidence":"No relapse; pelvic MRI 2022-10-25 showed no abnormal soft tissue in pelvis.","type":"Unknown"},"SCENE":"Maintenance_surveillance_followup","STAGE":{"stage_basis":"Unknown","stage_system":"Unknown","stage_text":"Unknown"},"SURGERY_DONE":{"date":"2021-08-26","performed":"Yes","procedure":"Radical hysterectomy with bilateral salpingo-oophorectomy, pelvic mass resection, partial rectosigmoid resection, sigmoid colostomy, omentectomy, pelvic lymphadenectomy, appendectomy, paraaortic lymphadenectomy"},"TIMELINE":{"constraints":{"max_events":30,"min_events":3,"must_include":["first diagnostic imaging or pathology confirmation (if available)"],"ordering_rules":{"prioritize_last_event":true}},"events":[{"date":"2021-08-26","description":"Primary cytoreductive surgery including radical hysterectomy, bilateral salpingo-oophorectomy, bowel resection, omentectomy, lymphadenectomy, colostomy, appendectomy","event_type":"Surgery","key_result":"Multiple peritoneal sites and 6/24 lymph nodes positive for carcinoma","regimen_or_test":"Surgery"},{"date":"2021-08-26","description":"Pathology confirmed high-grade serous carcinoma of bilateral ovaries with widespread peritoneal involvement and nodal metastases","event_type":"Diagnosis","key_result":"High-grade serous carcinoma, bilateral ovaries; 6/24 lymph nodes positive","regimen_or_test":"Pathology"},{"date":"2021-09-06","description":"Intraperitoneal chemotherapy with cisplatin 50mg","event_type":"Chemo","key_result":"Completed over 2021-09-06 and 2021-09-07","regimen_or_test":"顺铂50mg腹腔化疗"},{"date":"2021-10-18","description":"Started TP chemotherapy, planned 6 cycles","event_type":"Chemo","key_result":"Completed 6 cycles, last on 2022-03-22","regimen_or_test":"TP"},{"date":"2022-03-22","description":"Last cycle of TP chemotherapy","event_type":"Chemo","key_result":"Adjuvant chemotherapy completed","regimen_or_test":"TP"},{"date":"2022-04-18","description":"Complete blood count showing thrombocytopenia","event_type":"Lab","key_result":"PLT:33","regimen_or_test":"Blood routine"},{"date":"2022-04-26","description":"Stopped niraparib due to strong adverse reactions","event_type":"Other","key_result":"Maintenance paused","regimen_or_test":"尼拉帕利"},{"date":"2022-05-23","description":"Restarted niraparib 1# qd","event_type":"Chemo","key_result":"Maintenance resumed","regimen_or_test":"尼拉帕利"},{"date":"2022-06-24","description":"Abdominal wall hernia repair at Zhongshan Hospital","event_type":"Surgery","key_result":"Niraparib held for 3 weeks around surgery","regimen_or_test":"Surgery"},{"date":"2022-09-27","description":"CT chest/abdomen showing small bilateral pleural effusions improved; pulmonary AV fistula and nodules similar to prior","event_type":"Imaging","key_result":"No new malignant findings reported; abdominal details deferred","regimen_or_test":"CT"},{"date":"2022-10-08","description":"CT showing liver segment VII hemangioma and left renal cyst, stable","event_type":"Imaging","key_result":"No new findings; chest to correlate with other exams","regimen_or_test":"CT"},{"date":"2022-10-25","description":"Pelvic MRI after ovarian cancer surgery","event_type":"Imaging","key_result":"No abnormal soft tissue in pelvis; follow-up recommended","regimen_or_test":"MR"},{"date":"2022-12-30","description":"Zhongshan Hospital evaluation: incisional hernia, low-density lesion in right liver lobe","event_type":"Imaging","key_result":"Blood count and liver/kidney function generally acceptable","regimen_or_test":"Imaging"},{"date":"2023-01-09","description":"Recent blood routine showed platelet count 34 (year not fully specified)","event_type":"Lab","key_result":"PLT:34 (interpreted from 'PLT:342022.5.23起恢复', year unclear)","regimen_or_test":"Blood routine"}]},"VISIT_DATE":"2023-01-09","first_relapse_date":"Unknown","last_platinum_end_date":"2022-03-22"},"CLINICAL_TRIALS":[],"LAB_TRENDS":{"labs":[{"analyte":"Other","history":[{"date":"2022-04-18","flag":"↓","value":"PLT:33"}],"latest":{"date":"2022-04-18","flag":"↓","value":"PLT:33"},"reference_range":"Unknown","unit":"Unknown"}],"milestones":[{"date":"2021-08-26","description":"Primary debulking surgery for ovarian cancer","type":"Surgery"},{"date":"2021-10-18","description":"Started TP chemotherapy","type":"ChemoStart"},{"date":"2022-03-22","description":"Completed TP chemotherapy","type":"ChemoEnd"},{"date":"2022-04-18","description":"Thrombocytopenia (PLT 33) on blood routine","type":"Other"}]},"MED_ONC":{"current_regimen":{"cycle_info":"Continuous oral maintenance; temporarily stopped 2022-04-26 and around 2022-06-24 surgery; currently continuing","last_admin_date":"Unknown","name":"尼拉帕利"},"genetic_testing":{"germline":[],"somatic":["HRD"]},"monitoring_points":[{"drug_or_class":"尼拉帕利","monitoring":["Monitor platelet count due to prior thrombocytopenia"]}],"planned_next_regimen":"Unknown","prior_systemic_therapies":["顺铂50mg腹腔化疗","TP"]},"NUC_MED":{"studies":[]},"PATHOLOGY":{"specimens":[{"components":["High-grade serous carcinoma","Myometrial leiomyomas","Chronic cervicitis"],"date":"2021-08-26","diagnosis":"Adenocarcinoma consistent with high-grade serous carcinoma","grade":"High-grade","ihc":[],"involvement_sites":["Left ovary","Right ovary","Left fallopian tube","Right fallopian tube","Uterine myometrium","Pelvic and abdominal peritoneum","Partial rectosigmoid colon from serosa to superficial muscle","Omentum","Left paracolic gutter peritoneum","Small bowel mesentery","Sigmoid mesentery","Appendiceal serosa","Pelvic lymph nodes","Para-aortic and mesenteric lymph nodes (some positive)"],"laterality":"Bilateral ovarian involvement","molecular":[{"result":"Positive","test":"HRD"}],"raw_text":"术后病理：标本类型:扩大子宫+双附件+巨大盆块+部分直乙结肠+盆腹腔多病灶肿瘤大小:左侧：3.5×2×1.5cm；右侧：6×5.5×4.5cm肿瘤侧别:双侧病理类型:腺癌，结合免疫组化结果（I2021-07819），符合高级别浆液性癌。其他部位情况:左输卵管:见癌累及右输卵管:见癌累及子宫内膜:萎缩改变宫颈:慢性炎子宫肌层:见癌累及；肌壁间平滑肌瘤（多枚，直径0.5-2cm）盆腹腔多部位病灶:（部分直乙结肠）见癌累及，自浆膜层浸润至浅肌层，肠管两切缘未见癌累及。（大网膜、大网膜及盆腔肿块、左侧结肠旁沟腹膜、小肠系膜肿瘤、乙状结肠系膜肿瘤）见癌累及.（阑尾及周围肿块） 浆膜层见癌累及。其他:送检淋巴结（6/24）见癌转移，其中：左盆腔淋巴结（1/4）；右盆腔淋巴结（3/8）；腹主肠系膜下方淋巴结（1/4）； 肠系膜下动脉上方淋巴结（1/2）；腹主动脉旁淋巴结（0/6）。","sample_type":"Surgical resection","site":"Uterus, bilateral adnexa, pelvic mass, rectosigmoid colon, peritoneum, omentum, appendix, lymph nodes","tumor_size":"Left ovary 3.5×2×1.5cm; right ovary 6×5.5×4.5cm","uncertainty_or_missing":["FIGO stage not provided","IHC panel details not provided"]}]},"RADIOLOGY":{"next_imaging_plan":{"modality":"Unknown","timing":"Unknown"},"studies":[{"anatomic_sites":["Lung","Pleura","Chest"],"date":"2022-09-27","findings":["Right upper lung arteriovenous fistula similar to prior","Right upper lung apical segment small nodule similar to prior","Left upper lung scattered tiny nodules","Small bilateral pleural effusions decreased compared with prior","Scattered chronic inflammatory and fibrotic changes in lungs","Atelectasis improved","Nodule at right cardiophrenic angle less apparent"],"impression":"Pulmonary AV fistula and nodules unchanged; pleural effusions and atelectasis improved","modality":"CT","trend_vs_prior":"Improved"},{"anatomic_sites":["Liver","Kidney","Spine"],"date":"2022-10-08","findings":["Hemangioma in liver right lobe segment VII similar to prior","Left renal cyst similar to prior","Localized uneven sclerotic change in lumbar vertebrae similar to prior"],"impression":"Stable hemangioma and renal cyst; spinal sclerosis unchanged; chest findings to correlate with other exams","modality":"CT","trend_vs_prior":"Stable"},{"anatomic_sites":["Pelvis"],"date":"2022-10-25","findings":["Postoperative changes after ovarian cancer surgery","No abnormal soft tissue mass in pelvis"],"impression":"No pelvic recurrence; follow-up recommended","modality":"MRI","trend_vs_prior":"Stable"}]},"TIMELINE":{"constraints":{"max_events":30,"min_events":3,"must_include":["first diagnostic imaging or pathology confirmation (if available)"],"ordering_rules":{"prioritize_last_event":true}},"events":[{"date":"2021-08-26","description":"Primary cytoreductive surgery including radical hysterectomy, bilateral salpingo-oophorectomy, bowel resection, omentectomy, lymphadenectomy, colostomy, appendectomy","event_type":"Surgery","key_result":"Multiple peritoneal sites and 6/24 lymph nodes positive for carcinoma","regimen_or_test":"Surgery"},{"date":"2021-08-26","description":"Pathology confirmed high-grade serous carcinoma of bilateral ovaries with widespread peritoneal involvement and nodal metastases","event_type":"Diagnosis","key_result":"High-grade serous carcinoma, bilateral ovaries; 6/24 lymph nodes positive","regimen_or_test":"Pathology"},{"date":"2021-09-06","description":"Intraperitoneal chemotherapy with cisplatin 50mg","event_type":"Chemo","key_result":"Completed over 2021-09-06 and 2021-09-07","regimen_or_test":"顺铂50mg腹腔化疗"},{"date":"2021-10-18","description":"Started TP chemotherapy, planned 6 cycles","event_type":"Chemo","key_result":"Completed 6 cycles, last on 2022-03-22","regimen_or_test":"TP"},{"date":"2022-03-22","description":"Last cycle of TP chemotherapy","event_type":"Chemo","key_result":"Adjuvant chemotherapy completed","regimen_or_test":"TP"},{"date":"2022-04-18","description":"Complete blood count showing thrombocytopenia","event_type":"Lab","key_result":"PLT:33","regimen_or_test":"Blood routine"},{"date":"2022-04-26","description":"Stopped niraparib due to strong adverse reactions","event_type":"Other","key_result":"Maintenance paused","regimen_or_test":"尼拉帕利"},{"date":"2022-05-23","description":"Restarted niraparib 1# qd","event_type":"Chemo","key_result":"Maintenance resumed","regimen_or_test":"尼拉帕利"},{"date":"2022-06-24","description":"Abdominal wall hernia repair at Zhongshan Hospital","event_type":"Surgery","key_result":"Niraparib held for 3 weeks around surgery","regimen_or_test":"Surgery"},{"date":"2022-09-27","description":"CT chest/abdomen showing small bilateral pleural effusions improved; pulmonary AV fistula and nodules similar to prior","event_type":"Imaging","key_result":"No new malignant findings reported; abdominal details deferred","regimen_or_test":"CT"},{"date":"2022-10-08","description":"CT showing liver segment VII hemangioma and left renal cyst, stable","event_type":"Imaging","key_result":"No new findings; chest to correlate with other exams","regimen_or_test":"CT"},{"date":"2022-10-25","description":"Pelvic MRI after ovarian cancer surgery","event_type":"Imaging","key_result":"No abnormal soft tissue in pelvis; follow-up recommended","regimen_or_test":"MR"},{"date":"2022-12-30","description":"Zhongshan Hospital evaluation: incisional hernia, low-density lesion in right liver lobe","event_type":"Imaging","key_result":"Blood count and liver/kidney function generally acceptable","regimen_or_test":"Imaging"},{"date":"2023-01-09","description":"Recent blood routine showed platelet count 34 (year not fully specified)","event_type":"Lab","key_result":"PLT:34 (interpreted from 'PLT:342022.5.23起恢复', year unclear)","regimen_or_test":"Blood routine"}]},"TOXICITIES":[{"attribution":"Probable","dose_modification":"Yes","onset_date":"2022-04-18","outcome":"Resolved","related_line":"1L","related_regimen":"尼拉帕利","severity":"Severe","toxicity":"Strong adverse reaction to niraparib with thrombocytopenia (PLT 33)"}]}

# MUTATION / GENETIC REPORTS (Full Text for Trial Matching)
⚠️ COMPREHENSIVE NGS PANEL (~20,000 genes) - INTERPRETATION RULES:
• '未检出' (not detected) = NO pathogenic mutation found
• '（视为阴性）' (considered negative) = NO pathogenic mutation found
• '阴性' (negative) = negative result
• Genes with specific variants (e.g., 'NM_xxx:exon:c.xxx:p.xxx') = POSITIVE mutation
• If a gene is NOT mentioned, it means NO pathogenic mutation (comprehensive panel)

## Mutation Report 1 (ID: OH2201222, Date: 2022-01-24)
HRD 阳性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PALB2 胚系和体系未检出致病突变（视为阴性）；RAD51D 胚系和体系未检出致病突变（视为阴性）；BRIP1 胚系和体系未检出致病突变（视为阴性）；BARD1 胚系和体系未检出致病突变（视为阴性）


AVAILABLE TRIALS (compact; use id/name exactly as shown):
[
  {
    "id": "345",
    "name": " 评估JSKN003在中国晚期恶性实体瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的I/II期临床研究",
    "phase": "II期",
    "conditions": null,
    "line_of_therapy": "2、3、4L",
    "biomarker": null,
    "doctor": "李佳佳",
    "sponsor": "江苏康宁杰瑞生物制药有限公司",
    "lead_or_participation": "牵头",
    "treatment": "JSKN003-102（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）",
    "key_inclusion": "1、HER2 表达（IHC≥1+）\n\n2、经标准治疗失败、不能耐受标准治疗\n\n或缺乏有效治疗手段的受试者；",
    "key_exclusion": "",
    "contacts": [
      "王 涛"
    ],
    "phones": [
      "18721569326"
    ],
    "_raw": {
      "id": "345",
      "项目名称": " 评估JSKN003在中国晚期恶性实体瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的I/II期临床研究",
      "医生": "李佳佳",
      "试验治疗/用药": "JSKN003-102（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）",
      "期别": "II期",
      "申请单位": "江苏康宁杰瑞生物制药有限公司",
      "牵头/参与": "牵头",
      "目标受试者治疗线数": "2、3、4L",
      "入组排除标准": "1、HER2 表达（IHC≥1+）<br />\r\n2、经标准治疗失败、不能耐受标准治疗<br />\r\n或缺乏有效治疗手段的受试者；<br />",
      "联系人": [
        "王 涛"
      ],
      "联系电话": [
        "18721569326"
      ]
    }
  },
  {
    "id": "346",
    "name": "一项评价Trastuzumab Deruxtecan (T-DXd DS-8201a）治疗选定 HER2过表达肿瘤患者的有效性和安全性的多中心、开放性 II期研究（ DESTINY-PanTumor03)",
    "phase": "II期",
    "conditions": null,
    "line_of_therapy": "＞1线",
    "biomarker": null,
    "doctor": "朱 俊",
    "sponsor": "阿斯利康投资（中国）有限公司",
    "lead_or_participation": "牵头",
    "treatment": "Trastuzumab Deruxtecan（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）",
    "key_inclusion": "1、可预筛检测HER2 要求HER2 过表达（IHC≥1+）\n\n2、经标准治疗失败、不能耐受标准治疗\n\n或缺乏有效治疗手段的受试者；",
    "key_exclusion": "",
    "contacts": [
      "江文燕"
    ],
    "phones": [
      "15664735519"
    ],
    "_raw": {
      "id": "346",
      "项目名称": "一项评价Trastuzumab Deruxtecan (T-DXd DS-8201a）治疗选定 HER2过表达肿瘤患者的有效性和安全性的多中心、开放性 II期研究（ DESTINY-PanTumor03)",
      "医生": "朱 俊",
      "试验治疗/用药": "Trastuzumab Deruxtecan（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）",
      "期别": "II期",
      "申请单位": "阿斯利康投资（中国）有限公司",
      "牵头/参与": "牵头",
      "目标受试者治疗线数": "＞1线",
      "入组排除标准": "1、可预筛检测HER2 要求HER2 过表达（IHC≥1+）<br />\r\n2、经标准治疗失败、不能耐受标准治疗<br />\r\n或缺乏有效治疗手段的受试者；<br />",
      "联系人": [
        "江文燕"
      ],
      "联系电话": [
        "15664735519"
      ]
    }
  },
  {
    "id": "348",
    "name": "一项评估MRG004A在组织因子阳性的晚期或转移性实体瘤患者中的安全性、耐受性、有效性和药代动力学的开放、多中心、I/II期剂量递增和扩展临床研究",
    "phase": "I期",
    "conditions": null,
    "line_of_therapy": "2L、3L",
    "biomarker": null,
    "doctor": "郭勤浩、 Ⅰ期： 刘汝娇、 高水平、 陈 阳",
    "sponsor": " 上海美雅珂生物技术有限责任公司",
    "lead_or_participation": "牵头",
    "treatment": "MRG004A（ADC，靶向组织因子（tissue factor，TF））",
    "key_inclusion": "1、必须有组织学或细胞学证实的不切除或转移性肿瘤，标准治疗期间进展或经治后复发、进展。",
    "key_exclusion": "",
    "contacts": [
      "杨 珂"
    ],
    "phones": [
      "17774582517"
    ],
    "_raw": {
      "id": "348",
      "项目名称": "一项评估MRG004A在组织因子阳性的晚期或转移性实体瘤患者中的安全性、耐受性、有效性和药代动力学的开放、多中心、I/II期剂量递增和扩展临床研究",
      "医生": "郭勤浩、 Ⅰ期： 刘汝娇、 高水平、 陈 阳",
      "试验治疗/用药": "MRG004A（ADC，靶向组织因子（tissue factor，TF））",
      "期别": "I期",
      "申请单位": " 上海美雅珂生物技术有限责任公司",
      "牵头/参与": "牵头",
      "目标受试者治疗线数": "2L、3L",
      "入组排除标准": "1、必须有组织学或细胞学证实的不切除或转移性肿瘤，标准治疗期间进展或经治后复发、进展。",
      "联系人": [
        "杨 珂"
      ],
      "联系电话": [
        "17774582517"
      ]
    }
  },
  {
    "id": "350",
    "name": "评价注射用BL-B01D1在复发或转移性妇科恶性肿瘤等多种实体瘤患者中的安全性、耐受性、药代动力学及有效性的Ib/II期临床研究",
    "phase": "Ⅰb/Ⅱ 期",
    "conditions": null,
    "line_of_therapy": "2L、3L",
    "biomarker": null,
    "doctor": "吴 勇、刘汝娇 、高水平",
    "sponsor": "成都百利多特生物药业有限责任公司",
    "lead_or_participation": "牵头",
    "treatment": "单臂研究\n\n注射用BL-B01D1（ADC，靶向靶向 EGFR 和 HER3 靶点，毒性分子：拓扑异构酶I 抑制剂）",
    "key_inclusion": "1、经病理组织学和/或细胞学确诊的标准治疗失败或不耐受或目前尚无标准治疗的复发或转移性妇科恶性肿瘤",
    "key_exclusion": "",
    "contacts": [
      "李 想"
    ],
    "phones": [
      "17703993082"
    ],
    "_raw": {
      "id": "350",
      "项目名称": "评价注射用BL-B01D1在复发或转移性妇科恶性肿瘤等多种实体瘤患者中的安全性、耐受性、药代动力学及有效性的Ib/II期临床研究",
      "医生": "吴 勇、刘汝娇 、高水平",
      "试验治疗/用药": "单臂研究<br />\r\n注射用BL-B01D1（ADC，靶向靶向 EGFR 和 HER3 靶点，毒性分子：拓扑异构酶I 抑制剂）<br />",
      "期别": "Ⅰb/Ⅱ 期",
      "申请单位": "成都百利多特生物药业有限责任公司",
      "牵头/参与": "牵头",
      "目标受试者治疗线数": "2L、3L",
      "入组排除标准": "1、经病理组织学和/或细胞学确诊的标准治疗失败或不耐受或目前尚无标准治疗的复发或转移性妇科恶性肿瘤",
      "联系人": [
        "李 想"
      ],
      "联系电话": [
        "17703993082"
      ]
    }
  },
  {
    "id": "351",
    "name": " 一项评价HSK39775片单药用于晚期实体恶性肿瘤患者中的安全性、耐受性、PK/PD特征及初步有效性的Ⅰ/Ⅱ期临床研究",
    "phase": "Ⅰ期",
    "conditions": null,
    "line_of_therapy": "＞1线",
    "biomarker": null,
    "doctor": "李佳佳、刘汝娇",
    "sponsor": "西藏海思科制药有限公司",
    "lead_or_participation": "牵头",
    "treatment": "HSK39775片（泛素特异性蛋白酶1抑制剂，USP1i）",
    "key_inclusion": "既往接受过标准治疗或标准治疗不耐受或无标准治疗或无法获得标准治疗；",
    "key_exclusion": "",
    "contacts": [
      "张倩野"
    ],
    "phones": [
      "18627004197"
    ],
    "_raw": {
      "id": "351",
      "项目名称": " 一项评价HSK39775片单药用于晚期实体恶性肿瘤患者中的安全性、耐受性、PK/PD特征及初步有效性的Ⅰ/Ⅱ期临床研究",
      "医生": "李佳佳、刘汝娇",
      "试验治疗/用药": "HSK39775片（泛素特异性蛋白酶1抑制剂，USP1i）",
      "期别": "Ⅰ期",
      "申请单位": "西藏海思科制药有限公司",
      "牵头/参与": "牵头",
      "目标受试者治疗线数": "＞1线",
      "入组排除标准": "既往接受过标准治疗或标准治疗不耐受或无标准治疗或无法获得标准治疗；",
      "联系人": [
        "张倩野"
      ],
      "联系电话": [
        "18627004197"
      ]
    }
  },
  {
    "id": "353",
    "name": "在晚期恶性实体瘤患者中评价注射用西罗莫司（白蛋白结合型）的安全性、耐受性、药代动力学特征以及初步疗效的I期临床研究",
    "phase": "Ⅰ期",
    "conditions": null,
    "line_of_therapy": "＞1线",
    "biomarker": null,
    "doctor": "刘汝娇",
    "sponsor": " 石药集团中奇制药技术（石家庄）有限公司",
    "lead_or_participation": "参与（天津市肿瘤医院 郝继辉）",
    "treatment": "注射用西罗莫司（白蛋白结合型）",
    "key_inclusion": "1、标准治疗失败或无标准治疗患者",
    "key_exclusion": "",
    "contacts": [
      "刘 涵"
    ],
    "phones": [
      "19109628595"
    ],
    "_raw": {
      "id": "353",
      "项目名称": "在晚期恶性实体瘤患者中评价注射用西罗莫司（白蛋白结合型）的安全性、耐受性、药代动力学特征以及初步疗效的I期临床研究",
      "医生": "刘汝娇",
      "试验治疗/用药": "注射用西罗莫司（白蛋白结合型）",
      "期别": "Ⅰ期",
      "申请单位": " 石药集团中奇制药技术（石家庄）有限公司",
      "牵头/参与": "参与（天津市肿瘤医院 郝继辉）",
      "目标受试者治疗线数": "＞1线",
      "入组排除标准": "1、标准治疗失败或无标准治疗患者",
      "联系人": [
        "刘 涵"
      ],
      "联系电话": [
        "19109628595"
      ]
    }
  },
  {
    "id": "354",
    "name": "一项评价注射用DR30206治疗晚期实体瘤患者的安全性、耐受性和药代动力学特征的多中心、开放性I期临床研究",
    "phase": "Ⅰ期",
    "conditions": null,
    "line_of_therapy": "＞1线",
    "biomarker": null,
    "doctor": "吴 勇",
    "sponsor": " 浙江道尔生物科技有限公司",
    "lead_or_participation": "参与（组长单位：上海市肺科医院）",
    "treatment": "注射用DR30206（靶向 PD-L1、VEGF 和 TGFβ 的抗体融合蛋白）",
    "key_inclusion": "1、充分标准治疗失败或不耐受标准治疗或无有效标准治疗\n\n2、HPV 16+",
    "key_exclusion": "",
    "contacts": [
      "浦东/郭 伟 、徐汇/江文艳"
    ],
    "phones": [
      "13156793722、15664735519"
    ],
    "_raw": {
      "id": "354",
      "项目名称": "一项评价注射用DR30206治疗晚期实体瘤患者的安全性、耐受性和药代动力学特征的多中心、开放性I期临床研究",
      "医生": "吴 勇",
      "试验治疗/用药": "注射用DR30206（靶向 PD-L1、VEGF 和 TGFβ 的抗体融合蛋白）",
      "期别": "Ⅰ期",
      "申请单位": " 浙江道尔生物科技有限公司",
      "牵头/参与": "参与（组长单位：上海市肺科医院）",
      "目标受试者治疗线数": "＞1线",
      "入组排除标准": "1、充分标准治疗失败或不耐受标准治疗或无有效标准治疗<br />\r\n2、HPV 16+<br />",
      "联系人": [
        "浦东/郭 伟 、徐汇/江文艳"
      ],
      "联系电话": [
        "13156793722、15664735519"
      ]
    }
  },
  {
    "id": "358",
    "name": "评估JSKN033在中国晚期恶性实体瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的I/II期临床研究",
    "phase": "Ⅰ期",
    "conditions": null,
    "line_of_therapy": "2-3线",
    "biomarker": null,
    "doctor": "张 剑 、李佳佳",
    "sponsor": "江苏康宁杰瑞生物制药有限公司",
    "lead_or_participation": "牵头",
    "treatment": "JSKN033注射液（HER2 双特异性抗体偶联药物（ADC，毒性分子：拓扑异构酶I 抑制剂）与 PD-L1 抑制剂的高浓度皮下注射复方制剂）",
    "key_inclusion": "1、标准治疗失败或无标准治疗患者",
    "key_exclusion": "",
    "contacts": [
      "徐汇/牛紫嫣 浦东/刘雅琦"
    ],
    "phones": [
      "15638299516 18636833967 "
    ],
    "_raw": {
      "id": "358",
      "项目名称": "评估JSKN033在中国晚期恶性实体瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的I/II期临床研究",
      "医生": "张 剑 、李佳佳",
      "试验治疗/用药": "JSKN033注射液（HER2 双特异性抗体偶联药物（ADC，毒性分子：拓扑异构酶I 抑制剂）与 PD-L1 抑制剂的高浓度皮下注射复方制剂）",
      "期别": "Ⅰ期",
      "申请单位": "江苏康宁杰瑞生物制药有限公司",
      "牵头/参与": "牵头",
      "目标受试者治疗线数": "2-3线",
      "入组排除标准": "1、标准治疗失败或无标准治疗患者",
      "联系人": [
        "徐汇/牛紫嫣 浦东/刘雅琦"
      ],
      "联系电话": [
        "15638299516 18636833967 "
      ]
    }
  },
  {
    "id": "359",
    "name": "SHR-4375注射液在晚期实体瘤患者中的安全性、耐受性、药代动力学及疗效的开放、单臂、多中心的I/II期临床研究",
    "phase": "Ⅰ期",
    "conditions": null,
    "line_of_therapy": ">2L",
    "biomarker": null,
    "doctor": "张 剑 、李佳佳 、刘汝娇、 高水平",
    "sponsor": "苏州盛迪亚生物医药有限公司",
    "lead_or_participation": "牵头",
    "treatment": "SHR-4375（ADC ，靶向TF，毒性分子：拓扑异构酶I 抑制剂）",
    "key_inclusion": "1、组织学确诊的子宫颈癌；\n\n2、标准治疗失败或无标准治疗患者",
    "key_exclusion": "",
    "contacts": [
      "黄洋洋"
    ],
    "phones": [
      "13226861415"
    ],
    "_raw": {
      "id": "359",
      "项目名称": "SHR-4375注射液在晚期实体瘤患者中的安全性、耐受性、药代动力学及疗效的开放、单臂、多中心的I/II期临床研究",
      "医生": "张 剑 、李佳佳 、刘汝娇、 高水平",
      "试验治疗/用药": "SHR-4375（ADC ，靶向TF，毒性分子：拓扑异构酶I 抑制剂）",
      "期别": "Ⅰ期",
      "申请单位": "苏州盛迪亚生物医药有限公司",
      "牵头/参与": "牵头",
      "目标受试者治疗线数": ">2L",
      "入组排除标准": "1、组织学确诊的子宫颈癌；<br />\r\n2、标准治疗失败或无标准治疗患者<br />",
      "联系人": [
        "黄洋洋"
      ],
      "联系电话": [
        "13226861415"
      ]
    }
  },
  {
    "id": "361",
    "name": "一项旨在携带HER2激活突变的转移性或不可切除实体瘤参与者中评价口服可逆性酪氨酸激酶抑制剂BAY 2927088的有效性和安全性的II期、开放性、篮式研究",
    "phase": "II期",
    "conditions": null,
    "line_of_therapy": "＞1线",
    "biomarker": null,
    "doctor": "李佳佳",
    "sponsor": "Bayer Consumer Care AG",
    "lead_or_participation": "参与",
    "treatment": "单臂研究\n\nBAY 2927088（TKI，靶向HER2）",
    "key_inclusion": "1、标准治疗失败或无标准治疗患者；\n\n2、HER2激活突变（本院或认证的机构）；\n\n3、需提供肿瘤组织切片。",
    "key_exclusion": "",
    "contacts": [
      "李金山"
    ],
    "phones": [
      "18893190113 "
    ],
    "_raw": {
      "id": "361",
      "项目名称": "一项旨在携带HER2激活突变的转移性或不可切除实体瘤参与者中评价口服可逆性酪氨酸激酶抑制剂BAY 2927088的有效性和安全性的II期、开放性、篮式研究",
      "医生": "李佳佳",
      "试验治疗/用药": "单臂研究<br />\r\nBAY 2927088（TKI，靶向HER2）<br />",
      "期别": "II期",
      "申请单位": "Bayer Consumer Care AG",
      "牵头/参与": "参与",
      "目标受试者治疗线数": "＞1线",
      "入组排除标准": "1、标准治疗失败或无标准治疗患者；<br />\r\n2、HER2激活突变（本院或认证的机构）；<br />\r\n3、需提供肿瘤组织切片。<br />",
      "联系人": [
        "李金山"
      ],
      "联系电话": [
        "18893190113 "
      ]
    }
  }
]

DECISION RULE (be conservative):
Recommend ONE trial ONLY IF ALL are true:
1) Cancer type / primary site clearly matches.
2) Disease setting clearly matches (e.g., recurrent/advanced/metastatic and line is not fundamentally unclear).
3) Required biomarker/subtype is explicitly present in case text (if trial requires it).
4) No more than 2 critical eligibility confirmations remain.

If ANY of the above is not satisfied -> output None.

OUTPUT TEMPLATE (EXACT; no extra text):

Trial Recommendation:
- id: <trial id or None>
- name: <trial name or None>
- Reason: <1 short sentence>
- Missing eligibility confirmations (0-2 items):
  - item1 (or "None")
  - item2
  
  **Assistant:** Trial Recommendation:
- id: None
- name: None
- Reason: Patient is on first-line maintenance with no evidence of progression.
- Missing eligibility confirmations (0-2 items):
  - None
  
  *(2026-01-22T18:41:21.758149)*

